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ABSTRACT 
Re-thinking the Role of Ribosomal Proteins in the Mdm2-p53 Axis 
Lilyn Daftuar 
 
The Mdm2-p53 axis is an important pathway in cells that is frequently 
misregulated in cancer. Under basal conditions, Mdm2 suppresses p53 through 
multiple mechanisms. However, when stress is encountered, this suppression is 
lifted and p53 transactivates the expression of many target genes to effect 
outcomes such as cell cycle arrest and apoptosis. One type of stress that can 
activate p53 is ribosomal stress, also called nucleolar stress. Ribosomal stress 
occurs when mishaps occur in ribosomal biogenesis, and various ribosomal 
proteins (RPs) have been shown to signal to Mdm2 and activate p53. This thesis 
presents two studies in the regulation of the Mdm2-p53 axis by ribosomal 
proteins. 
In the first study, three ribosomal proteins are newly linked to the Mdm2-
p53 axis. RPL37, RPS15, and RPS20 are shown to bind to Mdm2, inhibit its E3 
ubiquitin ligase activity towards itself and p53, upregulate various p53 target 
genes, and cause both G2 arrest and apoptosis. Additionally, they downregulate 
levels of MdmX, a homolog of Mdm2 that also suppresses p53 activity. 
In the second study, a novel extra-ribosomal function has been identified 
for RPL36A. Unlike other ribosomal proteins that interact with and activate the 
Mdm2-p53 axis, RPL36A represses it. RPL36A enhances the E3 ubiquitin ligase 
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This thesis is divided into four chapters. Chapter one is an introduction to 
the Mdm2-p53-MdmX network, ribosomes and ribosomal proteins (RPs), and 
their intersection. Chapter two is modified from a manuscript published in PLOS 
ONE entitled “Ribosomal proteins RPL37, RPS15, and RPS20 regulate the 
Mdm2-p53-MdmX network.” Chapter three is a manuscript in preparation 
describing the regulation of the p53-Mdm2 axis by RPL36A. Chapter four 














THE MDM2-P53-MDMX NETWORK 
Discovery of p53 and its importance 
When thinking of cancer, a disease characterized by uncontrolled cellular 
proliferation, one must consider p53, the so-called “guardian of the genome 
(Lane, 1992). p53 is an important tumor suppressor in cells, and its loss or 
mutation has been implicated in at least half of all cases of human cancers 
(Levine and Oren, 2009). The earliest reports showed its locus on the short arm 
of chromosome 17 was lost in 75% of cases of colorectal carcinoma (Vogelstein 
et al., 1988) and the gene was mutated in a similar proportion of lung cancer 
(Takahashi et al., 1989). In particular, many cancers show loss of heterozygosity 
in which the wild-type allele is deleted from its locus, and the other allele is 
expressed as a missense mutation (Baker et al., 1989; Nigro et al., 1989). 
p53 was first discovered in 1979 (Kress et al., 1979; Lane and Crawford, 
1979; Linzer and Levine, 1979; Melero et al., 1979) as a protein that bound to the 
large T antigen of Simian vacuolating virus 40 (SV40), a DNA virus that is 
present in primate populations and has been shown to cause cancer in hamsters 
(Cicala et al., 1993). p53 was so named because it runs at 53kD on an SDS-
PAGE gel, and it was initially thought of as an oncogene in part because early 





non-transformed cells, and it could cooperate with oncogenes such as Ras to 
transform cells (DeLeo et al., 1979; Eliyahu et al., 1984; Parada et al., 1984). 
However, it was later determined that the early experiments were performed 
using a mutant form of p53 that had acquired oncogenic properties, and wildtype 
p53 functions as a tumor suppressor (Finlay et al., 1989; Hinds et al., 1989). 
(After its gene was cloned, its sequence revealed that p53 has a molecular mass 
of only 44kD.) 
Supporting its importance as a tumor suppressor, p53 is targeted for 
inactivation by all known DNA tumor viruses such as SV40, human 
papillomavirus (HPV), and Epstein-Barr virus (EBV) (Collot-Teixeira et al., 2004). 
Cancer also frequently arises spontaneously in the absence of viral infection, and 
further evidence for the importance of p53 in cancer comes from the study of Li-
Fraumeni, a human genetic disorder. Li-Fraumeni patients inherit a defective 
allele of p53 and are extremely cancer-prone (Malkin et al., 1990; Srivastava et 
al., 1990), as are mice engineered to carry mutant p53 genes (Lavigueur et al., 
1989) and knockout mice that lack both copies of p53 (Donehower et al., 1992).  
Further underlining the importance of p53, knock-in mice carrying a hyper-
active form of p53 are protected from cancer (Tyner et al., 2002), as are mice 
with an increased genetic dose of p53 (Garcia-Cao et al., 2002). Furthermore, 
restoring p53 function in various mouse models leads to tumor regression 
(Martins et al., 2006; Ventura et al., 2007; Xue et al., 2007). It should be noted 





frequently mutated. Mutant forms of p53 can function as a dominant-negative, 
interfering with wildtype p53 function, or can function as a gain-of-function 
mutation and exert novel oncogenic effects (Brosh and Rotter, 2009). 
 
Structure of p53 and its functions in cells 
p53 and its family members p63 and p73 are highly conserved among 
vertebrates (Lane et al., 2011; Lu et al., 2009), and p53 homologs have been 
identified in several invertebrate species including placozoans, arachnids, 
nematodes, and flies (Lane et al., 2010a; Lane et al., 2010b; Rutkowski et al., 
2010). Human p53 is a 393 amino acid protein that consists of a N-terminal 
transactivation domain (TAD1, residues 1-40, TAD2 residues 41-61) and a 
proline-rich region (PRR, residues 62-93). The central region of p53 contains a 
DNA binding domain (DBD, residues 94-292), a linker region (residues 293-324) 
harboring a nuclear localization signal (NLS), and a tetramerization domain (TET, 
residues 325-356) harboring a nuclear export signal (NES). Finally, the C-
terminus of p53 consists of a C-terminal regulatory domain (CTD, residues 357-
393) that harbors two additional NLSs (Figure 1.1). 
The N-terminus and the C-terminus of p53 are unstructured (Dawson et 
al., 2003), as is the linker region separating the DBD from the TET domain. Thus, 
while the crystal structures of both the TET domain and the DBD  have been 
solved down to the atomic level (Chen et al., 2010; Cho et al., 1994; Jeffrey et 





and of the entire protein, remain elusive. However, the N-terminus can be 
stabilized and crystalized if bound to RPA (Bochkareva et al., 2005), as can the 
C-terminus if bound to 14-3-3 (Schumacher et al., 2010). Additionally, both the N-
terminus and the entire protein have been visualized using nuclear magnetic 
resonance (NMR) imaging (Tidow et al., 2007; Wells et al., 2008) or cryo-electron 
microscopy (Okorokov et al., 2006). 
In the cell, p53 acts as a stress-responsive sequence-specific transcription 
factor that stimulates or downregulates expression of numerous target genes 
(Beckerman and Prives, 2010; Laptenko and Prives, 2006). The DBD of p53 
recognizes a symmetrical 20 base pair consensus sequence in target genes: a 
5’-PuPuPuC(A/T)(T/A)GPyPyPy-3' 10-mer that is separated from a second 10-
mer by 0-13 base pairs (el-Deiry et al., 1992; Funk et al., 1992; Riley et al., 
2008). Each half-site is bound by two p53 molecules, and the binding of a dimer 
of dimers is necessary to induce target gene transcription (Ho et al., 2006; 
Joerger and Fersht, 2008; Kitayner et al., 2006; Klein et al., 2001; Malecka et al., 
2009; Rippin et al., 2002). Perhaps three of the most well studied p53 targets are 
Mdm2, p21, and Puma, each associated with different cellular outcomes upon 
activation by p53. As described below, Mdm2 is important for downregulating p53 
levels and activity, thus the induction of Mdm2 by p53 creates an important 
negative feedback loop for shutting down p53 activity in cells. p21 (also known as 
Waf1, Cip1, or Cdkn1a) plays an important role in arresting the cell cycle and 





p21 binds to CDK2 and inhibits it from phosphorylating Rb. As a result, 
E2Fs remain sequestered and are unable to commence DNA replication (Nevins, 
2001). p21 also binds to proliferating cell nuclear antigen (PCNA) and prevents it 
from interacting with DNA polymerase delta during DNA replication and repair 
(Cayrol et al., 1998). Both mechanisms allow for efficient arrest in the G1 phase 
of the cell cycle, although p21 can also stimulate arrest in other parts of the cell 
cycle by inhibiting the activity of other CDKs. It should also be noted that p21 can 
be activated through p53-independent pathways (Abbas and Dutta, 2009). 
Puma induces apoptosis by binding to and inhibiting the anti-apoptotic 
protein Bcl2 and its family members (Nakano and Vousden, 2001). This releases 
the pro-apoptotic proteins Bax and Bak, which stimulate permeabilization of the 
mitochondrial outer membrane and release of cytochrome C (Chipuk and Green, 
2008). p53 can also directly induce the expression of Bax (Miyashita et al., 1994) 
or the pro-apoptotic Bcl2 family member Noxa (Oda et al., 2000; Shibue et al., 
2003), and has multiple other mechanisms to stimulate apoptosis (Chipuk and 
Green, 2006). 
Besides autoregulation, cell cycle arrest, and apoptosis, p53 also plays 
additional roles in DNA repair, metabolism, autophagy, embryo implantation, and 
more (Vousden and Prives, 2009) by stimulating the expression of target genes 
such as p53R2 (Tanaka et al., 2000), Sco2 (Matoba et al., 2006), Tigar (Bensaad 
et al., 2006), Dram (Crighton et al., 2006), and Lif (Hu et al., 2007). p53 also has 





activate senescence by binding to and stabilizing the mRNA of plasminogen 
activator inhibitor-1 (Pai-1) (Kortlever and Bernards, 2006; Shetty et al., 2008). 
Furthermore, cytoplasmic p53 can stimulate apoptosis by promoting the 
oligomerization of the pro-apoptotic protein Bax at the mitochondrial membrane 
(Baptiste and Prives, 2004; Chipuk et al., 2004; Erster et al., 2004). 
 
Regulation of p53 by Mdm2 and MdmX 
Given its importance in cell cycle arrest and apoptosis and other cellular 
outcomes, p53 is tightly regulated by Mdm2 (which stands for “Mouse Double 
Minute 2” and is also known as Hdm2) and its closely related homolog MdmX 
(also known as Mdm4 or HdmX). Both Mdm’s are RING (which stands for “Really 
Interesting New Gene”) domain-containing proteins that are highly conserved 
among vertebrates, and an Mdm gene has also been identified in invertebrates 
(Lane et al., 2011; Lane and Verma, 2012; Momand et al., 2011). 
Human Mdm2 is a 491 amino acid protein with distinct domains. It 
contains a N-terminal p53-binding domain (residues 18-101) that has been 
crystallized in complex with p53 (Kussie et al., 1996) and observed alone by 
NMR (Uhrinova et al., 2005). The N-terminus is separated from a central acidic 
domain (AD, residues 237-288) by a flexible linker that contains both a NLS and 
a NES. Adjacent to the AD is a Zinc finger domain (residues 289-331) whose 
structure has been determined by NMR (Yu et al., 2006). At the C-terminus of 





(residues 437-482). MdmX is similar in size and structure to Mdm2 at 490 amino 
acids, although it lacks NLS, NES, and NoLS sequences (Figure 1.2). Mdm2 and 
MdmX interact with each other through their RING domains (Tanimura et al., 
1999), and the crystal structures of the two RING domains bound together has 
been solved (Linke et al., 2008). But it is important to note that while the RING 
domain of Mdm2 functions as an active E3 ubiquitin ligase, transferring ubiquitin 
onto lysines of target proteins, the RING domain of MdmX is inactive (Sharp et 
al., 1999). 
The N-termini of both Mdm2 and MdmX can bind to the N-terminus of p53 
to inhibit its transactivation activity (Chen et al., 1993; Momand et al., 1992; 
Oliner et al., 1993). In the case of Mdm2, secondary sites of interaction have 
been identified between the central region of Mdm2 (residues 235-300) and p53 
(Kulikov et al., 2006), and between the N-terminus of Mdm2 and the C-terminus 
of p53 (Poyurovsky et al., 2010). 
Mdm2 has additional well-established mechanisms for regulating p53 
besides inhibiting its transactivation activity. One group found that the RING 
domain of Mdm2 can bind to p53 mRNA and suppress its translation (Candeias 
et al., 2008). But the most well studied function of the Mdm2 RING domain is to 
ubiquitinate the C-terminal domain of p53 (Haupt et al., 1997; Honda et al., 1997; 
Kubbutat et al., 1997), although both the acidic domain (Kawai et al., 2003b; 
Meulmeester et al., 2003) and extreme C-terminus (Poyurovsky et al., 2007; 





species, p53 is degraded by the 26S proteasome when poly-ubiquitinated, but as 
a result of mono-ubiquitination by Mdm2, p53 is preferentially exported from the 
nucleus (Lohrum et al., 2001). In the cytoplasm, the formation of Mdm2-p300 or 
Mdm2-CBP E3-E4 complexes facilitates the efficient production of poly-
ubiquitinated p53 species (Grossman et al., 2003; Shi et al., 2009). MdmX 
supports this function of Mdm2 by forming hetero-oligomers that stabilize it and 
direct its ubiquitination activity towards p53 (Stad et al., 2000); in the absence of 
MdmX, Mdm2 homo-oligomers form and preferentially trans-ubiquitinate and 
autodegrade (Wade et al., 2010). 
While the cell contains other E3 ubiquitin ligases that can ubiquitinate p53 
(Jain and Barton, 2010), studies in mice demonstrate the importance of Mdm2 
and MdmX in regulating p53. Mdm2 is essential for keeping p53 in check, since 
Mdm2-/- knockout mice are early embryonic lethals while p53-/- Mdm2-/- double 
knockout mice survive (Jones et al., 1995; Montes de Oca Luna et al., 1995). 
Similarly, MdmX-/- knockout mice die in utero (Finch et al., 2002), while p53-/- 
MdmX-/- double knockout mice survive (Parant et al., 2001), indicating the 
importance of both Mdm’s in regulating p53 during embryonic development. The 
importance of both Mdm2 and Mdm2 in regulating p53 in adult tissues has also 
been explored using conditional knockout and knockin mice. Deletion of either 
Mdm2 or MdmX from neuronal progenitor cells or post-mitotic neurons leads to 
p53-dependent apoptosis (Francoz et al., 2006; Xiong et al., 2006). Similarly, if 





ER mouse model, then unregulated p53 leads to death of the mouse or arrest of 
proliferating hematopoetic cells (Ringshausen et al., 2006; Garcia et al., 2011). 
However, it should be noted that Mdm2 and MdmX exhibit p53-
independent functions too (Manfredi, 2010; Wade et al., 2013). For example, 
Mdm2 downregulates p21 protein levels in an ubiquitin-independent manner (Jin 
et al., 2003), and if Mdm2 is knocked down by siRNA, p21 is synthesized but is 
unable to induce cell cycle arrest (Giono and Manfredi, 2007). Mdm2 also binds 
to Nbs1, a DNA repair protein, and inhibits repair of double strand breaks (Alt et 
al., 2005). Additionally, several mouse models suggest p53-independent roles 
exist for Mdm2 in vivo. If Mdm2 is overexpressed throughout a mouse, it can 
cause a unique variety of tumors to arise, different from the tumor pattern seen in 
p53-null mice (Jones et al., 1998). Mdm2 degradation targets outside of the 
Mdm2-p53-MdmX network may contribute to its p53-independent oncogenic 
functions. For example, Mdm2 can ubiquitinate and degrade Rb (Uchida et al., 
2005), leading to cell cycle progression.  Mdm2 can also target Numb for 
degradation (Juven-Gershon et al., 1998). Numb is involved in nervous system 
development system and is responsible for inhibiting Notch signaling in 
proliferating cells, so Mdm2-mediated degradation may inappropriately activate 
Notch signaling. In the case of MdmX, the data from mouse models is less clear. 
One study found overexpressing MdmX was not tumorigenic (De Clercq et al., 
2010) while another study found it was tumorigenic (Xiong et al., 2010). Since 





transcription factor E2F1 (Strachan et al., 2003), perhaps its p53-independent 
anti-proliferative properties are more relevant in vivo. 
Finally, it should be noted that, unlike p53, Mdm2 and MdmX are rarely 
mutated in human cancers; rather they are often amplified or overexpressed 
(Momand et al., 1998; Wade and Wahl, 2009). The few cases of mutant Mdm2 
that have been identified are missense mutations within the central acidic region. 
As described below, the central acidic region of Mdm2 is also the site of 
interaction for various ribosomal proteins, and disrupting their interactions has 
implications in vivo. 
 
Activation of p53 in response to stress 
Thus, although p53 is continually produced in cells, its rapid ubiquitination 
and degradation means it has a short half-life and levels of it are kept low. But 
upon the introduction of stress, Mdm2 and p53 are modified so that Mdm2 
cannot bind to it and target it for degradation. As a result, levels of p53 can rise 
rapidly and the cell can quickly respond to the stress (Figure 1.3). Cellular stress 
can come in many forms, the first of which to be identified was DNA damage 
induced by ultraviolet (UV) irradiation (Maltzman and Czyzyk, 1984). UV 
irradiation causes the formation of pyrimidine dimers that can be repaired by 
nucleotide excision repair (NER), while ionizing radiation (IR) causes double-
strand breaks (DSBs) in DNA that can be repaired by homologous recombination 





In HR, the MRN complex (consisting of Mre11, Rad50, and Nbs1) binds to 
the broken ends to stabilize them, and recruits ATM, an essential 
serine/threonine (S/T) kinase that is strongly tumorigenic when mutated (Barlow 
et al., 1996; Chun and Gatti, 2004) and whose kinase activity is necessary for 
maintaining genomic stability (Yamamoto et al., 2012). ATM facilitates DNA 
repair, cell cycle arrest and apoptosis by phosphorylating many targets including 
itself, Mre11, Nbs1, Sae2 and H2AX (Baroni et al., 2004; Burma et al., 2001; 
Lavin, 2007). Sae2 is the endonuclease response for resecting the broken DNA 
to generate single-stranded DNA that is capable of invading the homologous 
chromosome, the first step in HR (Symington and Gautier, 2011). ATM also 
phosphorylates Chk2, another S/T kinase, which goes on to phosphorylate p53 
on S20 in the N-terminus (Chehab et al., 2000; Hirao et al., 2000; Shieh et al., 
2000) and on S366, S378, and T387 in the C-terminus (Ou et al., 2005). 
ATM also directly phosphorylates p53 on S15 (Canman et al., 1998) and 
S46 (Kodama et al., 2010), Mdm2 on both its N-terminus (Khosravi et al., 1999) 
and on S395 in the RING domain (Maya et al., 2001), and MdmX on S342, S367, 
and S403 (Chen et al., 2005). Other kinases can also phosphorylate p53 and 
Mdm2, such as DNA-PK, an S/T kinase involved in NHEJ (Mayo et al., 1997; 
Shieh et al., 1997). The effect of phosphorylated Mdm2 is to prevent it from 
interacting with and degrading p53 (Chen, 2012), and a recent study found 
phospho-Mdm2 can also bind to p53 mRNA to stimulate its translation (Gajjar et 





where Mdm2 was found to bind to p53 mRNA and suppress its translation 
(Candeias et al., 2008).) Finally, after the stress has passed, p53 can shut itself 
down by upregulating levels of both Mdm2 and Wip1 (also known as Ppm1d), a 
phosphatase that can de-phosphorylate both p53 and Mdm2 (Fiscella et al., 
1997; Lu et al., 2007; Takekawa et al., 2000). 
DNA damage also affects MdmX levels and localization in a modification-
dependent manner. Early studies found ectopic MdmX is predominantly 
cytoplasmic basally but re-localizes to the nucleus after DNA damage (Li et al., 
2002). However, other studies have found that levels of endogenous MdmX drop 
in response to (non-lethal) stress due to an increase in Mdm2-mediated 
ubiquitination (Kawai et al., 2003a). Levels of MdmX may also drop in response 
to the p53-mediated upregulation of miR-34a, a micro RNA that can target 
various mRNAs, such as MdmX mRNA, for RISC-mediated degradation (Mandke 
et al., 2012; Markey and Berberich, 2008). As a result of the decreased levels of 
MdmX, the formation of Mdm2 homo-oligomers that trans-ubiquitinate may be 
favored, rather than the formation of Mdm2-MdmX hetero-oligomers that target 
p53 for degradation. In mice, if residues S342, S367, and S403 are mutated such 
that they can no longer be phosphorylated by ATM or Chk2 in response to DNA 
damage, then MdmX degradation is inhibited and p53 activation is attenuated 
(Wang et al., 2009). Similarly, if MdmX is overexpressed in mice, the mice exhibit 





cellular MdmX associates with Bcl2 at mitochondria and can facilitate p53-
mediated apoptosis in response to a lethal dose of UV (Mancini et al., 2009). 
Besides phosphorylation by kinases, other binding partners can modify 
p53 and Mdm2 in response to DNA damage or other forms of stress. For 
example, p300 is an acetyl transferase that can bind the N-terminus of phospho-
p53 (Meek and Anderson, 2009), acetylate p53 on K382 and other residues in 
response to UV or IR (Sakaguchi et al., 1998), and play an important role in 
inhibiting p53’s interaction with Mdm2 and promoting p53 stability after stress (Ito 
et al., 2001; Tang et al., 2008). The C-terminus of p53 can also be modified by 
the addition of methyl, Nedd8, or Sumo moieties (Carter and Vousden, 2009), 
and various post-translational modifications to p53 may be associated with 
different cellular outcomes (Carvajal and Manfredi, 2013; Vousden and Prives, 
2009). For example, modifications to the two transactivation domains within the 
N-terminus of p53 (TAD1 and TAD2) promote the transactivation of different 
target genes. When TAD1 is modified in response to DNA damage, p21 is 
induced and cell cycle arrest follows. On the other hand, modifications to TAD2 
following oncogene activation tend to promote apoptosis (Brady et al., 2011).  
Besides DNA damage, many other forms of stress can also activate p53, 
such as include hypoxia, heat shock, spindle damage, nutritional starvation, and 
more (Vousden and Prives, 2009). In the case of oncogenic stress, Arf (which 
stands for “Alternate Reading Frame”) plays an important role. Arf is a nucleolar 





phosphorylation and progression of the cell cycle beyond G1. The expression of 
the alternate reading frame of this locus, rather than Ink4a, is induced by 
activation oncogenes such as Ras or Myc, and Arf can interact with the central 
acidic domain of Mdm2 and sequester it in the nucleolus, allowing p53 to be 
activated (Weber et al., 1999; Zhang et al., 1998). Arf overexpression can also 
lead to the addition of Sumo moieties onto Mdm2, followed by inhibition of Mdm2 





RIBOSOMES AND RIBOSOMAL PROTEINS 
Ribosome structure and function 
Ribosomes are highly conserved structures consisting of both proteins 
and nucleic acids responsible for protein synthesis in all living cells. The crystal 
structures of the 70S prokaryotic bacterial ribosome and the 80S eukaryotic 
yeast ribosome have been solved (Ban et al., 2000; Ben-Shem et al., 2011; 
Jenner et al., 2012; Mitra et al., 2005; Schluenzen et al., 2000; Schuwirth et al., 
2005; Wimberly et al., 2000). The eukaryotic ribosome is significantly larger than 
the bacterial ribosome due to the increased length and number of strands of 
catalytic rRNA, as well as the introduction of 47 additional ribosomal proteins 
(RPs) that have no bacterial homolog. In the case of human ribosomes, the 40S 
small subunit consists of 33 proteins (RPS2 – RPS30) surrounding 1 strand of 
rRNA (18S), while the 60S large subunit consists of 46 proteins (RPL2 – RPL41) 
surrounding 3 strands of rRNA (5S, 5.8S, and 28S). In addition, mitochrondria 
have their own ribosomes with their own mitochondrial RPs (MRPs) and 
mitochondrial rRNAs organized into small and large subunits (Cavdar Koc et al., 
2001; Koc et al., 2001). Of particular note to the rest of this thesis are the RPs 
outlined in Figure 1.4. 
During protein synthesis, ribosomes translate mRNA into amino acids in a 
complex process (Dever and Green, 2012; Jackson et al., 2010). In the first step, 
the 40S small subunit recognizes mRNA and identifies the AUG start codon, 





During elongation, the active 80S ribosome travels along mRNA in the 5’-3’ 
direction, accepts charged tRNAs containing anticodons complementary to 
mRNA codon sequences, catalyzes peptide bond formation between the amine 
end of the newly accepted amino acid and the carboxy end of the growing 
polypeptide chain, and releases the emptied tRNA. While the rRNA component 
of ribosomes exhibit peptidyl transferase activity, the protein component of 
ribosomes drive major conformational changes after codon-anticodon matches 
have been produced. Finally, during termination, the stop codon is recognized, 
the nascent polypeptide is released, and the small and large ribosomal subunits 
separate in preparation for a new cycle of translation. 
 
Ribosomal biogenesis 
Ribosomal biogenesis occurs within the nucleolus of higher eukaryotes 
(Boisvert et al., 2007). Nucleoli are non-membrane bound compartments of 
nuclei that organize around clusters of rDNA genes during interphase. rDNA is 
transcribed into an immature 45S rRNA precursor by RNA polymerase I in the 
fibrillar center (FC) of the nucleolus, and snoRNPs such as nucleolin and 
fibrillarin process it into mature 5.8S, 18S, and 28S rRNAs in the dense fibrillar 
component (DFC) of the nucleolus. (5S rRNA is transcribed by RNA polymerase 
III in the nucleoplasm and then directed to the nucleolus for incorporation into 
nascent 60S large subunits.) Mature strands of rRNA then associate with 





with the help of proteins such as nucleophosmin (also known as NPM, B23, or 
numatrin). The assembled 40S small and 60S large subunits are finally exported 
from the nucleoplasm into the cytoplasm, and come together to form an active 
80S ribosome upon recruitment by eukaryotic initiation factors (eIFs) (Jackson et 
al., 2010).  
The genes encoding the RPs are transcribed into mRNA by RNA 
polymerase II, and in yeast, approximately 50% of RNA pol II transcripts are RP 
mRNAs (Warner, 1999). While RP mRNAs levels are carefully regulated in yeast 
and have short half-lives, RP mRNA levels vary and are relatively stable in higher 
eukaryotes (Perry, 2007). In both species, as with other protein-encoding genes, 
RP mRNAs are exported into the cytoplasm for translation. The translation of 
vertebrate RP mRNAs is carefully regulated by 5’ terminal oligopyrimidine (5’-
TOP) sequences that are targeted by growth pathways such as mTOR-SK61. 
The coordinate translation of RP mRNAs in response to mitogenic signals may 
help balance RP production and ensure the proper RP stoichiometry is achieved 
(Meyuhas, 2000). 
After synthesis, RPs enter the nucleus and are targeted to the nucleolus, 
where they assemble with 18S and 5S / 5.8S / 28S rRNAs to form the 40S small 
and 60S large ribosomal subunits, respectively. While RPs that have been 
incorporated into ribosomal subunits are stable with a half-life on the order of 
days, excess unassembled RPs have a half-life on the order of minutes and are 





energetically wasteful, this assures RPs are abundant and their availability is not 
rate limiting for ribosome production and cellular growth. Additionally, this rapid 
degradation may prevent RPs, which are highly basic and bind strongly to nucleic 
acids, from interacting with nucleoplasmic components inappropriately (Warner, 
1999).  
However, GFP-RPs have also been shown to shuttle slowly between the 
nucleolus and nucleoplasm, with fluorescence recovery after photopbleaching 
(FRAP) taking a few minutes. Similarly, proteins involved in rRNA transcription 
and processing also shuttle between the nucleolus and nucleoplasm, but much 
more rapidly (Chen and Huang, 2001). These results may not be too surprising, 
since nucleoli are not bound by any membranes, so proteins ought to be able to 
diffuse freely between nucleoli and the nucleoplasm. Presumably, only nascent 
RPs not yet bound to rRNA and not yet degraded can exhibit this movement, 
while RPs that have been incorporated into 40S or 60S ribosomal subunits 
cannot. Alternatively, some excess RPs may linger in the nucleoplasm and serve 
extra-ribosomal functions (Komili et al., 2007; Schroder and Moore, 2005; Wool, 
1996). 
 
Roles for ribosomal proteins beyond the ribosome 
While ribosomal proteins (RPs) are well understood in terms of their 
contribution to ribosome structure and function, there are increasing lines of 





2009). Several RPs can auto-regulate their own mRNA or influence RNA 
polymerase III transcription of tRNA and 5S rRNA. For example, yeast RPL2 and 
RPS28 both have been shown to regulate their own mRNA levels (Badis et al., 
2004; Presutti et al., 1991), and RPL30 and RPS14 can control splicing of their 
own mRNA (Eng and Warner, 1991; Fewell and Woolford, 1999). More recently, 
human RPS13 was also shown to bind its own mRNA and inhibit its splicing 
(Malygin et al., 2007), and RPS3 was shown to bind its own mRNA and inhibit its 
translation (Kim et al., 2010). Additionally, RPL6 can enhance RNA pol III activity 
in vitro (Dieci et al., 1993) and overexpressing it in yeast suppresses the growth 
defect caused by a mutant TFIIIC component (Dieci et al., 2009). 
And while not an extra-ribosomal function per se, it is interesting that the 
two genetic loci for ubiquitin in eukaryotic cells is the same locus as two RP 
genes, RPS27A and RPL40 (Catic and Ploegh, 2005; Finley et al., 1989). 
Ubiquitin plays an important role in targeting proteins for proteasome-mediated 
degradation (Hochstrasser, 1996), and like RPs, it is highly conserved, abundant, 
and widely expressed. Ubiquitin is co-transcribed and co-translated with either 
one of the RPs, and the joined precursor protein is separated immediately after 
translation. 
There are additional examples of RPs functioning outside of the ribosome 
and far afield from ribosomal biogenesis. Missense mutations were identified in 
RPL10 in two cases of autism (Klauck et al., 2006), and RPL10 has been found 





RPL22 was also shown to bind to histone H1 in flies (Ni et al., 2006), although 
the significance of these protein interactions remains unclear. More recently, 
RPL13A was shown to be phosphorylated in response to interferon-gamma 
(IFNg) treatment of U937 cells. Phospho-RPL13A leaves the ribosome to 
associate with the GAIT complex (Mazumder et al., 2003; Mukhopadhyay et al., 
2008) and reduce translation of specific target mRNAs such as 
ceruloplasmin and VEGF-A (Ray and Fox, 2007). Interestingly, despite the 
removal of RPL13A from ribosomes, protein translation appears to function 
normally. 
From the small ribosomal subunit, RPS3 was shown to contain a 
biochemically active endonuclease domain (Kim et al., 1995), although its role in 
DNA repair in vivo remains unclear. RPS3 has also been shown to interact with 
NFkB in response to TNF stimulation and relocate to the nucleoplasm (Wan et 
al., 2007), and interact with both Mdm2 and p53 in the nucleoplasm in response 
to oxidative stress (Yadavilli et al., 2009). Additionally, RPS26 was recently 
identified as a type 1 diabetes susceptibility gene in a genome-wide SNP 
association study (Schadt et al., 2008). 
Finally, a few RPs can directly regulate cellular growth. RPL23 was shown 
to bind to NPM, a nucleolar protein that helps rRNA and RPs assemble into small 
and large subunits, and prevent it from activating Miz1, an antagonist of the 
transcription factor Myc. Therefore, RPL23 can indirectly promote Myc activation 





RPS14 have been shown to bind to and inhibit the transactivation activity of Myc 
(Dai et al., 2007; Dai et al., 2010; Zhou et al., 2013b). RPL11 was further shown 
to downregulate Myc mRNA levels via micro-RNA silencing in response to 
ribosomal stress (Challagundla et al., 2011).  
 
Ribosomal proteins and cancer 
The importance of ribosomal biogenesis in cancer is perhaps suggested 
by the role of Arf, a tumor suppressor found in the nucleolus, in regulating it. Arf 
can suppress ribosomal subunit assembly by binding to NPM and inhibiting its 
function (Bertwistle et al., 2004). It can also suppress rRNA synthesis by binding 
to the RNA pol I transcription termination factor TTF1 and excluding it from the 
nucleolus (Lessard et al., 2010). When Arf is absent, cells have enlarged nucleoli 
and show increased ribosomal biogenesis (Apicelli et al., 2008). 
But more direct links between ribosomal proteins (RPs) and cancer exist. 
For example, relevant to the RPs that will be discussed in the remainder this 
thesis, levels of RPS15, RPS27A, RPL26, and RPL37 (among several dozen 
other RPs) are elevated in colorectal cancer (Lai and Xu, 2007), and more 
recently, a link between overexpression of RPS20 and adverse outcome in 
medulloblastoma has been reported (De Bortoli et al., 2006).  
Presumably, all RPs must be overexpressed in cancer simply to fuel the 
demands of rapidly growing cancer cells for increased polypeptide synthesis, and 





increase expression of proto-oncogenes aberrantly. For example, Akt can signal 
to mTOR to augment ribosomal biogenesis, and Myc can upregulate multiple 
targets including several RPs, RP processing proteins, and eIFs (Ruggero and 
Pandolfi, 2003). Indeed, pathologists have long observed enlarged or increased 
numbers of nucleoli in cancerous cells (Montanaro et al., 2008), and this 
“nucleolar hypertrophy” can serve as a prognostic marker in the clinic (Derenzini 
et al., 2009). Nevertheless, it is impossible to use correlations such as these to 
conclude a causative role exists for RPs in the development or prognosis of 
cancer.  
For many model organisms, loss of even one allele of several RP genes 
impairs growth. A “Minute” phenotype has been observed in mice heterozygous 
for mutant RPS19 or RPS20 (McGowan et al., 2008), flies carrying mutant RPS3 
(Saeboe-Larssen et al., 1998), and even plants whose levels of RPL23A were 
reduced used siRNA (Degenhardt and Bonham-Smith, 2008). In yeast, deletion 
of a single allele of RPS6 led to both a reduction in cell size and reduced growth 
rates (Chiocchetti et al., 2007). 
More persuasive evidence for a causative role for RPs in cancer comes 
from other studies. One study suggested RPS3A may function as an oncogene, 
since overexpressing it in 3T3 cells led to their transformation, and 
overexpressing it in nude mice led to tumor formation (Naora et al., 1998). On the 
other hand, a zebrafish genetic screen for essential haploinsufficient tumor 





(Amsterdam et al., 2004). Additionally, RPS6 was identified as a tumor 
suppressor in flies, since silencing its expression led to the formation of tumors 
and abnormal hematopoetic cell differentiation (Watson et al., 1992). This result 
could not be recapitulated in mice, since knocking out even one allele of RPS6 
resulted in embryonic lethality (Panic et al., 2006). However, eliminating its 
expression in the liver led to the cessation of hepatocellular division (Volarevic et 
al., 2000). Another study in mice identified a role for RPS19 and RPS20 in 
erythroid proliferation, since mutation of either one led to a reduction in the 
number of red blood cells (McGowan et al., 2008). 
Finally, in humans, Diamond-Blackfan anemia (DBA), an autosomal 
dominant inherited disorder characterized by increased apoptosis of erythroid 
cells and a predisposition to cancer (Ellis and Lipton, 2008), is caused by 
mutations to RP genes. The most common mutation is to RPS19, but rarer cases 
have been reported where RPs such as RPS7, RPS15, RPS26, RPL5, or RPL11 
are mutated (Badhai et al., 2009; Doherty et al., 2010; Gazda et al., 2008). 
Another human cancer-predisposition disease, 5q- syndrome, has been linked to 
mutations in RPS14 (Ebert et al., 2008). Additionally, aberrations in other aspects 
of ribosome function are also associated with cancer. Syndromes caused by 
mutation to rDNA production or rRNA processing genes include Cartilage-hair 
hypoplasia syndrome, Dyskeratosis congenita, Shwachman–Bodian–Diamond 
syndrome, and Treacher-Collins syndrome, and are also associated with defects 





 It should be noted that siRNA-mediated depletion of any of the RPs 
involved in DBA has been shown to lead to a decrease in levels of all of the RPs 
of the same ribosomal subunit, a decrease in levels of that ribosomal subunit, 
and reduced levels of fully assembled ribosomes and polysomes (Robledo et al., 
2008). Since this inhibition of ribosome function by knockdown of a RP leads to 
defects in cellular growth, it remains unclear how haploinsufficiency of a RP gene 
contributes to tumorigenesis in animals and suggests that the mechanisms by 





RIBOSOMAL PROTEINS AND MDM2 
Several ribosomal proteins interact with Mdm2 and regulate p53 
p53 can inhibit ribosomal biogenesis through multiple mechanisms (Budde 
and Grummt, 1999; Zhai and Comai, 2000), and loss of p53 function has been 
correlated with an upregulation in ribosome biogenesis (Montanaro et al., 2008). 
Conversely, overexpression of various ribosomal proteins (RPs) has been linked 
to an upregulation in p53 levels. The first of these to be described was RPL11, 
which can bind to Mdm2 and inhibit ubiquitination of p53 (Dai et al., 2006; 
Lohrum et al., 2003; Zhang et al., 2003). Although a physical interaction between 
Mdm2, p53, 5S rRNA, and RPL5 was identified prior to the RPL11-Mdm2 
interaction (Marechal et al., 1994), its significance was unclear for another 10 
years until it was shown that RPL5 can also inhibit Mdm2-mediated ubiquitination 
and degradation of p53 (Dai and Lu, 2004). Since then, multiple other RPs have 
also been shown to stabilize p53. These include RPL23 (Dai et al., 2004; Jin et 
al., 2004), RPL26 (Zhang et al., 2010), RPS7 (Chen et al., 2007; Zhu et al., 
2009), RPS14 (Zhou et al., 2013a), RPS25 (Zhang et al., 2013), RPS26 (Cui et 
al., 2013), RPS27, RPS27A and RPS27L (Sun et al., 2011; Xiong et al., 2011).  
All 11 of the RPs described above bind to the central region of Mdm2, and 
many of them can increase Mdm2 levels in addition to p53, although in several 
cases, it is unclear if they do so via p53 transcription (Figure 1.5). But a few clear 
differences between the RPs have been observed. For example, RPL26 has 





mediated ubiquitination. RPL26 binds to both the 5’ UTR and the 3’ UTR of p53 
mRNA to stimulate its translation after cells have been treated with ionizing 
radiation (Chen and Kastan, 2010; Takagi et al., 2005). When the cell is un-
stressed, RPL26 is ubiquitinated by Mdm2 and targeted for degradation, and is 
inhibited from interacting with p53 mRNA by both Mdm2 (Ofir-Rosenfeld et al., 
2008) and nucleolin (Chen et al., 2012). 
 Other ribosomal proteins are also modified by Mdm2, although under 
varying conditions and with various consequences. For example, like RPL26, 
Mdm2-mediated ubiquitination of RPS27L leads to its degradation (Xiong et al., 
2011), while Mdm2 only ubiquitinates and degrades RPS27A in response to 
actinomycin D (ActD)-induced ribosomal stress (Sun et al., 2011). On the other 
hand, Mdm2-mediated neddylation of RPL11 can protect it from degradation 
(Sundqvist et al., 2009). In the case of RPS7, Mdm2-mediated ubiquitination 
does not lead to its degradation. Rather, ubiquitinated RPS7 can no longer inhibit 
Mdm2 auto-ubiquitination but can still selectively inhibit the degradation of p53, 
creating a feed-forward loop whereby Mdm2 levels drop but p53 accumulates 
(Zhu et al., 2009).  
 Ribosomal proteins can also be differentiated from each other based upon 
their effect on MdmX or their status as p53 target genes. RPS14 does not 
interact with MdmX and has no effect on its levels (Zhou et al., 2013a), while 
overexpression of RPS25 stabilizes MdmX (Zhang et al., 2013). On the other 





(Gilkes et al., 2006). Interestingly, 5S rRNA was recently shown to be involved in 
MdmX stability (Li and Gu, 2011). Finally, transcription of RPS27 is repressed by 
p53, while RPS27L transcription is enhanced (Xiong et al., 2011). Transcription 
of RPS25 is also repressed by p53 in response to ribosomal stress (Zhang et al., 
2013).  
 
Ribosomal proteins signal to p53 following ribosomal stress 
Ribosomal biogenesis is an energetically expensive procedure for the cell. 
A mammalian cell spends approximately half of its resources on the creation of 
new ribosomes (Warner, 1999), so it makes sense for the cell to have evolved 
surveillance mechanisms to ensure its fidelity. Ribosomal stress, also known as 
nucleolar stress, occurs when mishaps occur in ribosomal biogenesis. These 
mishaps can arise from an inhibition to rRNA production or processing, an 
imbalance in RP levels, or an impairment to ribosomal subunit assembly (Boulon 
et al., 2010). Other types of stress that activate p53, such as DNA damage, 
oncogene activation or nutrient deprivation, have also been shown to trigger 
disruptions in nucleolar function (Rubbi and Milner, 2003). As a result, nucleoli 
may disintegrate and nucleolar proteins and RPs may relocalize into the 
nucleoplasm (Chen and Huang, 2001) and transduce ribosomal stress signals to 
p53. Mdm2 may also relocalize to nucleoli following ribosomal stress (Mekhail et 





Ribosomal stress can be induced in cells by the application of actinomycin 
D (ActD), 5-fluorouracil (5FU), or mycophenolic acid (MPA). In the case of ActD, 
a low dose interferes with RNA pol I transcription of rDNA (Perry and Kelley, 
1970), while 5FU can be incorporated into rRNA molecules and inhibit rRNA 
processing (Ghoshal and Jacob, 1994). MPA functions by inhibiting guanine 
nucleotide synthesis, leading to a block in rRNA transcription (Sun et al., 2008). 
In each of these cases, p53 levels are upregulated and cell cycle arrest or 
apoptosis is induced (Figure 1.6). Interestingly, several other drugs that are not 
thought of as ribosomal stress agents, such as cisplatin, doxorubicin, and 
MG132, can also disrupt transcription or rDNA or processing of rRNA (Burger et 
al., 2010). 
For each the 11 aforementioned RPs that can upregulate p53 levels when 
overexpressed (RPL5, RPL11, RPL23, RPL26, RPS7, RPS14, RPS25, RPS26, 
RPS27, RPS27A, RPS27L), their knockdown by siRNA generally leads to a 
decrease in basal p53 levels (the few exceptions are siRPL23, siRPS14, and 
siRPS26, which upregulate basal p53 levels). Additionally, each of these RPs is 
necessary for a full response to ribosomal stress. When ActD is applied, levels of 
p53 are lower in siRPL5, siRPL11, siRPL23, siRPS7, siRPS14, siRPS27A, or 
siRPS27L cells than in siControl cells, and p21 upregulation is attenuated as well 
(Dai and Lu, 2004; Dai et al., 2004; Jin et al., 2004; Sun et al., 2011; Xiong et al., 
2011; Zhou et al., 2013a; Zhu et al., 2009). In the case of siRPS25, p21 levels 





induced ribosomal stress (Zhang et al., 2013). Interestingly, levels of p53 protein 
were not affected by ActD in a siRPS26 background, but both Mdm2 and p21 
levels were decreased (Cui et al., 2013). (The ribosomal stress response in 
siRPL26 and siRPS27 cells has not been determined.) 
But in other cases, knockdown of a RP induces p53 rather than 
suppressing its activation. For example, siRNA directed against RPL7A, RPL22, 
RPL24, RPL29, RPL30, RPL37, RPS6, RPS9, and RPS23 all lead to increased 
levels of p53 (Anderson et al., 2007; Barkic et al., 2009; Fumagalli et al., 2009; 
Lindstrom and Nister, 2010; Llanos and Serrano, 2010; Sun et al., 2010). In 
these latter cases, decreasing the amount of a RPL or RPS appears to impair 
60S or 40S ribosomal subunit assembly within the cell, creating ribosomal stress 
that leads to activation of p53. These RPs also appear to function through RPL5 
and RPL11, since knocking either one down simultaneously leads to decreased 
levels of p53 rather than increased levels (Fumagalli et al., 2009; Sun et al., 
2010). RPL5 and RPL11 have also been shown to cooperate with each other for 
their function (Horn and Vousden, 2008), and one recent report suggested 
RPL11 and RPL5 may be especially important in transducing ribosomal stress 
signals to p53, since they accumulate in ribosomal-free fractions after ActD 
treatment, while several other RPs are rapidly degraded (Bursac et al., 2012). 
Thus, a model was hypothesized where RPs can be classified as 
“detector” or “effector” regulators of p53 (Daftuar et al., 2010; Llanos and 





because they bind to Mdm2, upregulate p53 when overexpressed by inhibiting 
Mdm2-mediated ubiquitination, and are necessary for a full p53 response to 
ribosomal stress. Detector RPs do not bind to Mdm2, have no effect on p53 
levels when overexpressed, but cause p53 levels to rise in an RPL11-dependent 
manner when knocked down by siRNA. Thus, detector RPs can be seen as 
indirect regulators of p53, and based upon this model, RPS12 may tentatively be 
classified as a detector RP, since a recent publication shows it fails to co-
immunoprecipitate with Mdm2 and fails to inhibit p53 degradation in cells (Sun et 
al., 2011). 
 
Additional roles for the RP-Mdm2-p53 pathway 
Several lines of evidence suggest that the interaction between effector 
RPs and Mdm2 has relevance in vivo. Besides being essential for responding to 
ribosomal stress, several RPs have been shown to play a role in the p53 
response to DNA damage. One report found that RPs move from the nucleolus 
to the nucleoplasm in a p53-dependent manner following etoposide treatment 
(Boisvert and Lamond, 2010), and RPS25 and RPL27L have been shown to be 
necessary for p53 levels to be fully induced (Xiong et al., 2011; Zhang et al., 
2013). Similarly, ionizing radiation normally strongly induces p53, but when 
RPL26 or RPL27L is ablated by siRNA, p53 induction is attenuated (Sun et al., 
2010; Xiong et al., 2011). Ablation of RPL11 or RPS7 by siRNA decreases p53 





doxorubicin, daunorubicin, neocarzinostatin, and hydroxyurea (Zhu et al., 2009). 
Finally, if siRPS26 cells are treated with doxorubicin, they exhibit less acetyl-p53 
and less transactivation of target genes such as Mdm2 and p21, although levels 
of total p53 and phospho-S15 p53 are maintained (Cui et al., 2013). 
RPs have also been shown to be important in the response to other forms 
of stress, both p53-dependent and Mdm2-dependent. Knockdown of RPS3 by 
siRNA leads to an attenuation of p53 upregulation in response to hydrogen 
peroxide-induced oxidative stress (Yadavilli et al., 2009). And RPS7 was recently 
shown to inhibit Mdm2-mediated ubiquitination and degradation of Gadd45a, and 
be necessary for induction of cell death mediated by the carcinogen arsenite 
(Gao et al., 2013). 
Furthermore, several studies demonstrate the importance of intact RP-
Mdm2-p53 pathways in humans, fish, and mice. Human diseases caused by 
mutations to RP genes (such as Diamond-Blackfan anemia and 5q- syndrome) 
are characterized by a predisposition to cancer, although the p53 status in 
patients is unclear. But deletion of one allele of 17 different RPs in zebrafish is 
tumorigenic, and this was recently linked to lower levels of (wildtype) p53 protein 
in the tumors (MacInnes et al., 2008). Finally, only a few tumor-derived missense 
mutations have been identified in Mdm2, and at least two of them (C305F and 
C308Y) show impaired binding to RPL5 and RPL11. These mutations maintain 
their ability to interact with Arf and suppress p53 transactivation, but cannot 





significantly, a Mdm2-C305F mouse has significantly accelerated tumor 
development in an Eµ-Myc model, and cells from the mouse fail to activate p53 in 
response to ActD, 5FU, or MPA -mediated ribosomal stress (Macias et al., 2010). 






NOVEL RIBOSOMAL RPOTEINS THAT MAY INTERACT WITH MDM2 
A previous lab member, Dr. Xavier Jacq, performed an extensive yeast 
two-hybrid (Y2H) screen (Zhu et al., 2009) and identified over 500 potential 
Mdm2 interacting proteins. 11 of these fell into the ribosomal protein (RP) family 
(Figure 1.7), and 5 of them (RPL11, RPL26, RPS7, RPS26, and RPS27A) have 
been published as bona fide interactors with Mdm2 and negative regulators of 
Mdm2-mediated ubiquitination of p53 (Chen et al., 2007; Cui et al., 2013; Lohrum 
et al., 2003; Sun et al., 2011; Takagi et al., 2005; Zhang et al., 2003). The rest of 
this thesis describes 4 of the remaining RPs identified by the Y2H screen, 
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Figure 1.1. Schematic of p53. The N-terminus of p53 contains two 
transactivation domains (TAD1/2) that are responsible for regulating transcription 
of target genes. A proline-rich region (PRR) lies in between them and the central 
DNA binding domain, which recognizes and binds to specific sequences in target 
genes. At the C-terminus of p53 is an oligomerization domain (OD) and a C-
terminal domain (CTD) that is modified both under basal conditions (ubiquitinated 
by Mdm2) and in response to stress (acetylated by p300). Figure is taken from 
(Joerger and Fersht, 2010). 
 
Figure 1.2. Schematic of Mdm2 and MdmX. Mdm2 and MdmX are negative 
regulators of p53 that inhibit p53 function by binding to its transactivation domain. 
Mdm2 can also function as a RING-type E3 ubiquitin ligase and target p53 for 
degradation, while the RING domain of MdmX is inactive as an E3 ubiquitin 
ligase. Mdm2 uses its N-terminus to bind to the N-terminus of p53 and its C-
terminal RING domain to ubiquitinate to C-terminus of p53, while the middle of 
Mdm2 contains a conserved acidic domain, Zinc finger, and nuclear localization 
and export signals. MdmX also binds to the N-terminus of p53 using its N-
terminus, and the two Mdm proteins interact with each other using their RING 
domains. The percent identities of the various domains are indicated. Figure is 






Figure 1.3. Model of p53 signaling pathway. Under conditions of cellular 
stress, p53 becomes modified such that Mdm2 can no longer bind to it and 
degrade it. This leads to an accumulation of p53, which can function as a 
transcription factor within the nucleus. The genes that p53 can transactivate 
determine various cellular outcomes such as cell cycle arrest or apoptosis. p53 
can also stimulate apoptosis in a transcription-independent way by binding to the 
pro-apoptotic proteins Bcl2 or BclX to activate permeabilization of outer 
mitochondrial membranes. 
 
Figure 1.4. Conservation of selected ribosomal proteins across species. 
Ribosomes are highly conserved structures across all forms of life, with larger, 
more complex structures in eukaryotes and simpler structures in prokaryotes. 
Research across decades led to a profusion of names for the various ribosomal 
proteins (RPs) found in E. coli, S. cerevisiae, and H. sapiens. Recently, a 
consensus nomenclature was proposed, and is summarized here for various RPs 
that will be further described. Figure is adapted from (Jenner et al., 2012). 
 
Figure 1.5. Ribosomal proteins that interact with Mdm2. 11 ribosomal 
proteins (RPs) have been shown to interact with Mdm2 and affect p53 levels 
when overexpressed. The four RPLs and 7 RPSs that have been published to do 






Figure 1.6. Model for upregulation of p53 by ribosomal proteins. Defects in 
ribosome transcription, processing, or assembly can lead to nucleolar stress that 
triggers cell cycle arrest. In 2009, 5 ribosomal proteins (RPL5, RPL11, RPL23, 
RPL26, and RPS7) were known to increase p53 levels by inhibiting Mdm2-
mediated degradation or by stimulating transcription of message; more have 
since been uncovered. Figure is taken from (Zhang and Lu, 2009). 
 
Figure 1.7. Candidate ribosomal proteins from Mdm2 yeast two-hybrid 
screen. 11 ribosomal protein (RP) genes were identified as “hits” in a yeast two-
hybrid screen utilizing Mdm2 as the bait (performed by Dr. Xavier Jacq at 
Hybrigenics in 2004). 5 of these have been shown to interact with Mdm2 in 
human cells, while 6 of these candidates are novel. 5 of the novel RP genes 
were cloned from a human cDNA library into the mammalian expression vector 
pcDNA3-Myc and their ability to interact with Mdm2 was confirmed by co-
immunoprecipitation assays in the indicated cell line(s). Their effect on p53 levels 
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ABSTRACT 
 Changes to the nucleolus, the site of ribosome production, have long been 
linked to cancer, and mutations in several ribosomal proteins (RPs) have been 
associated with an increased risk for cancer in human diseases. Relevantly, a 
number of RPs have been shown to bind to MDM2 and inhibit MDM2 E3 ligase 
activity, leading to p53 stabilization and cell cycle arrest, thus revealing a RP-
Mdm2-p53 signaling pathway that is critical for ribosome biogenesis surveillance. 
Here, we have identified RPL37, RPS15, and RPS20 as RPs that can also bind 
Mdm2 and activate p53. We found that each of the aforementioned RPs, when 
ectopically expressed, can stabilize both co-expressed Flag-tagged Mdm2 and 
HA-tagged p53 in p53-null cells as well as endogenous p53 in a p53-containing 
cell line. For each RP, the mechanism of Mdm2 and p53 stabilization appears to 
be through inhibiting the E3 ubiquitin ligase activity of Mdm2. Interestingly, 
although they are each capable of inducing cell death and cell cycle arrest, these 
RPs differ in the p53 target genes that are regulated upon their respective 
introduction into cells. Furthermore, each RP can downregulate MdmX levels but 
in distinct ways. Thus, RPL37, RPS15 and RPS20 regulate the Mdm2-p53-





   
INTRODUCTION 
p53 is an important tumor suppressor in cells, and its loss or mutation has 
been implicated in at least half of all human cancers (Levine and Oren, 2009). 
Molecularly, p53 is a transcription factor that stimulates expression of numerous 
target genes in response to stress (Vousden and Prives, 2009). Levels of p53 are 
tightly regulated by Mdm2, a RING-type E3 ubiquitin ligase that binds to the N-
terminal transactivation domain of p53 via sequences within its own N-terminal 
region. Mdm2 both inhibits p53 transactivation of its target genes and 
ubiquitinates lysines within the p53 C-terminus. Mdm2-mediated ubiquitination 
targets p53 for nuclear export and degradation by the proteasome (Toledo and 
Wahl, 2006). p53 activity is also regulated by MdmX, a homolog of Mdm2 that 
also contains a N-terminal p53-binding domain and a C-terminal RING domain 
(Shvarts et al., 1996). Just as with Mdm2, binding of the MdmX N-terminus to 
p53 inhibits its transactivation activity, but in the case of MdmX, its RING domain 
does not function to ubiquitinate p53. Rather, MdmX forms hetero-oligomers with 
Mdm2 in cells and likely directs Mdm2 RING activity towards p53 ubiquitination 
and away from Mdm2 auto-ubiquitination (Gu et al., 2002; Tollini and Zhang, 
2012). 
Upon some forms of cellular stress, MdmX is degraded, thus releasing 
p53 from inhibition (Biderman et al., 2012; Kawai et al., 2003), and Mdm2 and 
p53 are modified so that Mdm2 cannot bind to p53 and target it for degradation. 





   
depending on the extent of the damage or cellular context, apoptosis. The 
accumulation of p53 also stimulates expression of Mdm2, thus completing an 
important negative feedback loop whereby p53 is eventually degraded once the 
stress has passed (Kruse and Gu, 2009). It is noteworthy that, unlike p53, Mdm2 
and MdmX are only rarely mutated in human cancers; rather, they are sometimes 
amplified (Momand et al., 1998). The rare exceptions that have been identified 
for Mdm2 consist of a few missense mutations located within the central acidic 
region, which coincidentally is the same region that interacts with various 
ribosomal proteins (RPs).  
While the nucleolus had already been linked to p53 by multiple lines of 
evidence (Derezini et al., 2009), the first report to directly link a ribosomal protein 
(RP) to p53 identified a physical interaction between Mdm2, p53, 5S rRNA, and 
RPL5 (Marechal et al., 1994). The significance of this interaction was unclear 
until it was published that RPL11 can also bind Mdm2, and overexpressing this 
RP allowed for the inhibition of the ubiquitination and degradation of p53 (Lohrum 
et al., 2003; Zhang et al., 2003). RPL11 was also shown to stimulate the Mdm2-
mediated ubiquitination and degradation of MdmX (Gilkes et al., 2006). 
The interaction between RPL11 and Mdm2 is not a unique phenomenon 
since it was then shown that p53 can be stabilized in an Mdm2-dependent 
manner by ectopic expression of RPL5, RPL23, RPS7, RPS14, RPS25, as well 
as RPS27, RPS27A, and RPS27L. These RPs all bind to the central region of 





   
(Chen et al., 2007; Dai and Lu, 2004; Dai et al., 2004; Jin et al., 2004; Lohrum et 
al., 2003; Sun et al., 2011; Xiong et al., 2011; Zhang et al., 2013; Zhou et al., 
2013; Zhu et al., 2007). Although knockdown of these RPs by siRNA have 
varying impacts on p53 protein levels in the absence of stress, they attenuate the 
induction of p53 when ribosomal stress is introduced to cells. For example, 
siRPL5 (Dai and Lu, 2004) and siRPL11 (Lohrum et al., 2003) reduce levels of 
p53 both basally and in response to stress, while siRPL23 and siRPS14 increase 
levels of basal p53 but attenuate the p53 response to ribosomal stress (Dai et al., 
2004; Zhou et al., 2013). Furthermore, RPL5 and RPL11 were recently shown to 
accumulate in ribosomal-free fractions in response to actinomycin D (ActD)-
induced ribosomal stress (Bursac et al., 2012). Interestingly, the few tumor-
derived missense mutants of Mdm2 that have been identified impair binding to 
RPL5 and RPL11 while maintaining their interaction with p53 (Lindstrom et al., 
2007). Furthermore, a mouse bearing one of these mutations (Mdm2-C305F) 
was shown to have significantly accelerated tumor development in an Eµ-Myc 
mouse model (Macias et al., 2010).  
Another ribosomal protein, RPL26, was also shown to be a positive 
regulator of p53, but by more complex mechanisms. After irradiation of cells, 
RPL26 binds to both the 5’ UTR and 3’ UTR of p53 mRNA and stimulates its 
translation (Chen and Kastan, 2010; Takagi et al., 2005), while under non-
stressed conditions, RPL26 is targeted for degradation by Mdm2 and is inhibited 





   
recently, RPL26 was shown to stabilize p53 through inhibiting the ubiquitin ligase 
activity of Mdm2, similar to the RPs mentioned above (Zhang et al., 2010). 
Interestingly, the role of RPs in regulating p53 signaling through Mdm2 
interaction is not limited to ribosomal stress. It was shown that stress-induced 
p53 stabilization was attenuated by the various DNA damage agents after RPS7 
or RPL11 ablation (Zhu et al., 2009). Also, another RP from the 40S small 
subunit, RPS3, was shown to interact with both p53 and Mdm2, and knockdown 
of RPS3 by siRNA led to an attenuation of p53 upregulation in response to 
oxidative stress (Yadavilli et al., 2009).  
 Our experiments identify three new RPs, RPL37, RPS15, and RPS20, that 
bind to and regulate Mdm2 and MdmX, and thereby p53. While they each appear 
to function similarly to many of the other RPs described above in their regulation 
of Mdm2, we noted interesting differences among them in the modes by which 
they interact with Mdm2, in their respective abilities to regulate p53 target gene 
expression, and how they regulate MdmX protein levels. Such differences might 
eventually provide a clue as to why so many different RPs appear to be involved 





   
MATERIALS AND METHODS 
Plasmids and siRNA 
Flag-Mdm2 (full length and deletion constructs), HA-MdmX, HA-p53, HA-
ubiquitin, and GFP plasmids were described previously (Zhu et al., 2009). For 
Myc-RPs, total RNA was extracted from HEK293 cells (RNeasy Mini Kit, Qiagen) 
and a cDNA library was made by reverse-transcription (QuantiTect Reverse 
Transcription Kit, Qiagen). RPL37, RPS15, and RPS20 fragments were amplified 
from the cDNA library by PCR and cloned into the pcDNA3-Myc vector using the 
following primers: 5’-AAGGATCCAATGACGAAGGGAACGTCAT-3’ and 5’-
CCTCTAGATTAAGATGAACTGGATGCT-3’ for RPL37 forward and reverse, 
respectively; 5’-AAGGATCCAATGGCAGAAGTAGAGCAGA-3’ and 5’-
CCGAATTCTTACTTGAGAGGGATGAAG-3’ for RPS15 forward and reverse, 
respectively; and 5’-CCGGATCCAATGGCTTTTAAGGATACCG-3’ and 5’-
CCCTCGAGTTAAGCATCTGCAATGGTG-3’ for RPS20 forward and reverse, 
respectively. DNA sequences were confirmed using the NCBI reference 
database. siRNA sequences (Table 2.T1) were obtained commercially (Qiagen); 
siRPs were pre-designed by the manufacturer while control siRNA (siRNA versus 
luciferase; siLuc) was previously described (Peart et al., 2010). 
 
Cells culture and transfection 
U2OS osteosarcoma, SJSA osteosarcoma, and H1299 lung carcinoma cell lines 





   
plates prior to transfection, except where indicated. DNA transfections were 
performed for 24 hours with Lipofectamine 2000 (Invitrogen) or FuGENE6 
(Promega) according to the manufacturer’s instructions; siRNA transfections 
were performed for 72 hours with DharmFECT1 (Thermo Scientific) according to 
the manufacturer's instructions. All DNA transfections were balanced with 
pCDNA3-Myc to ensure equal amounts of total DNA were used, and all siRNA 
transfections were balanced with siLuciferase (Qiagen). Cells were harvested 24 
hours after DNA transfection or 72 hours after siRNA transfection. Frozen cell 
pellets were stored at -80 °C until processed for RNA or protein analyses. In the 
case of cell cycle analyses, cells were processed immediately upon harvesting. 
 
Antibodies and immunoblotting 
Transfected cells were lysed with 100 µl Lysis Buffer (25 mM Tris-Hcl pH 7.5, 
137 mM NaCl, 2.7 mM KCl, and 0.5% Igepal CA-630 supplemented with 50 nM 
PMSF and inhibitor cocktail containing 100uM Benzamidine, 300ug/uL 
Leupeptin, 100mg/mL Bacitracin, and 1mg/mL a2-macroglobulin), and cell 
lysates were cleared by spinning at 4,000 rpm for 10 minutes. Protein 
concentrations were determined by Bradford assay, and equivalent amounts of 
each transfected and clarified cell lysate was loaded onto a polyacrylamide gel 
and separated using constant voltage. Proteins were transferred onto 
nitrocellulose membranes (Bio-Rad), blocked, and probed using the following 





   
Santa Cruz Biotechnology); anti-HA (16B12, Covance); anti-Mdm2 (a mixture of 
3G5, 4B11, and 5B10 hybridomas); anti-MdmX (A300-287A, Bethyl 
Laboratories); anti-Myc (9E10, Santa Cruz Biotechnology or C3956, Sigma); anti-
p21 (C19, Santa Cruz Biotechnology); anti-p53 (a mixture of 1801 and D01 
hybridomas); anti-RPL37 (AP95656, Abgent); anti-RPS15 (AP6914a, Abgent); 
anti-RPS20 (ab74700, Abcam). Membranes were washed with PBS 
supplemented with 0.1% Tween 20 prior to the addition of secondary antibodies. 
In some cases, a goat anti-mouse or goat anti-rabbit conjugated to horseradish-
peroxidase (Sigma) was used, and membranes were visualized using ECL (GE 
Healthcare). In other cases, fluorescent green goat anti-mouse (IRDye 800CW, 
LI-COR Biosciences) and fluorescent red donkey anti-rabbit (IRDye 680LT, LI-
COR Biosciences) secondary antibodies were used in conjunction with the 
Odyssey Imaging System (LI-COR Biosciences). 
 
Immunoprecipitations 
H1299 cells were transfected with Myc-RPs, various Flag-Mdm2 constructs, or 
HA-MdmX as indicated. Equivalent amounts of each clarified cell lysate was 
subjected to immunoprecipitation with 1 µg of a monoclonal Myc antibody (9E10, 
Santa Cruz Biotechnology). For co-immunoprecipitation of endogenous proteins, 
confluent SJSA cells were lysed and cleared as described. SJSA cell lysates 
were pre-cleared with Protein G Sepharose beads (GE Healthcare) before 





   
monoclonal Mdm2 antibody (N20, Santa Cruz Biotechnology). Pre-blocked 
Protein G Sepharose beads were added to cell lysates for 45 minutes, and 
unbound proteins were removed by washing with Lysis Buffer. Samples were 
resuspended in Lysis Buffer and Protein Sample Buffer prior to boiling at 95 °C 
for 10 minutes. 
 
Ubiquitination assays 
H1299 cells were transfected with HA-Ubiquitin, p53, Flag-Mdm2, or Myc-RPs as 
indicated. 18 hours after transfection, H1299 cells were treated with 25 µM 
MG132 (Calbiochem) for 6 hours. Equivalent amounts of clarified cell lysates 
were immunoprecipitated with 1 µg of anti-p53 (in the case of Mdm2-mediated 
ubiquitination of transfected p53) or 1.9 µg of anti-Flag (in the case of auto-
ubiquitination of transfected Flag-Mdm2) followed by Western blot using anti-HA 
antibody to detect ubiquitinated p53 or Mdm2 species.  
 
Cycloheximide assay 
U2OS cells were transfected with empty vector (pcDNA3-Myc) or the indicated 
Myc-tagged RP as indicated. Approximately 23 hours after transfection, cells 
were treated with 100 µg/mL cycloheximide (Sigma) and harvested at the 
indicated time points. Cell lysates were subjected to immunoblotting with anti-p53 
and anti-actin antibodies, and band intensities were quantified using Odyssey 





   
actin, the protein half-life of p53 was calculated using a one-phase exponential 
decay model (GraphPad Prism). 
 
Quantitative RT-PCR 
U2OS cells were transfected with Myc-RP as indicated. Total RNA was extracted 
from transfected cell pellets using the RNeasy Mini Kit (Qiagen), and cDNA was 
synthesized using the QuantiTect Reverse Transcription Kit (Qiagen). Expression 
of each gene was determined in triplicate using SYBR Green (Applied 
Biosystems) on a StepOnePlus Real-Time PCR machine (Applied Biosystems). 
Each sample was normalized using GAPDH primers, and relative gene 
expressions were determined using the ΔΔCt method. Primer sequences (Table 
2.T2) were designed using Primer Express software (Applied Biosystems) and 
validated for efficiency and specificity prior to the start of experimentation. 
 
Cell cycle analysis 
U2OS cells were transfected with Myc-RP as indicated. Twenty-four hour after 
transfection, transfected cells were fixed and stained with propidium iodide (PI) 
as previously described (Peart et al., 2010) and analyzed using a FACS Calibur 
machine (BD Biosciences). Cell cycle distribution was determined using the 
ModFit LT program (Verity House Software), and sub-G1 content was 





   
RESULTS 
RPL37, RPS15, and RPS20 interact with Mdm2 
A yeast two-hybrid screen using Mdm2 as bait (Zhu et al., 2009) identified 
several RPs as potential interactors with Mdm2. Among the candidate Mdm2-
interacting RPs identified were RPL11 (Lohrum et al., 2003; Zhang et al., 2003), 
RPL26 (Takagi et al., 2005), RPS7 (Chen et al., 2007; Zhu et al., 2009), and 
RPS27A (Sun et al., 2011) which have been confirmed in published studies as 
bona fide interactors with Mdm2 and regulators of p53. Therefore, we sought to 
validate the additional RPs identified in the yeast two-hybrid screen by testing the 
interaction of RPL37, RPS15, and RPS20 with Mdm2 in mammalian cells. 
RPL37, RPS15, and RPS20 were cloned into a mammalian expression vector 
and transfected into H1299 lung carcinoma cells alongside Mdm2. When the 
transfected RPs were immunoprecipitated from the cell lysates, we found Mdm2 
could associate with each of these RPs (Figures 2.1a-c). Significantly, the H1299 
cell line is p53-null, indicating that the interactions of these three RPs with Mdm2 
is independent of p53. The presence of p53 did not abrogate the interactions, 
however, as a similar result was observed with transfected RPs and Mdm2 in the 
p53-containing U2OS osteosarcoma cell line (Figure 2.S1). We also confirmed 
an interaction between the endogenously expressed RPs and Mdm2 in the SJSA 
osteosarcoma cell line that harbors wild-type p53 (Figure 2.1d). 
We next sought to map the regions of Mdm2 that are responsible for 





   
RPS14) have each been shown to bind to the central acidic region or central Zinc 
finger region of Mdm2 (Dai and Lu, 2004; Dai et al., 2004; Lohrum et al., 2003; 
Zhou et al., 2013; Zhu et al., 2009). Using a panel of Mdm2 deletion constructs, 
we found that RPL37, RPS15, and RPS20 can also bind to the central Zinc finger 
region of Mdm2, between amino acids 273-339 (Figure 2.1e). A Mdm2 variant 
lacking residues 340-437 bound better than full-length Mdm2 to each of the RPs, 
suggesting the region spanning amino acids 340-437 inhibits their interaction 
(Figure 2.S2). Interestingly as well, RPS15 and RPS20 but not RPL37 can also 
interact (albeit weakly) with the N-terminal 220 amino acids of Mdm2, where the 
p53-interacting domain lies, as well as the C-terminus of Mdm2, where the RING 
domain lies (Figure 2.S2). This suggests either that the tertiary structure of 
MDM2 augments its interaction with these two RPs or that they possess 
additional binding surfaces for Mdm2. 
 
RPL37, RPS15, and RPS20 stabilize Mdm2 and p53 by inhibiting Mdm2 
ubiquitin ligase activity 
To determine the functional consequence of the physical interaction 
between RPL37, RPS15, and RPS20 and Mdm2, H1299 cells were transfected 
with a constant quantity of Flag-Mdm2 and increasing amounts of each Myc-RP. 
Levels of Flag-Mdm2 were increased by co-transfected RPs in a dose-dependent 
manner (Figure 2.2a). A similar stabilization of Flag-Mdm2 by these three RPs 





   
immuofluoresent microscopy (Figure 2.S3). As Mdm2 may control its own 
degradation through its ubiquitin ligase activity, we introduced HA-tagged 
ubiquitin into H1299 cells and confirmed that each RP can inhibit Mdm2 auto-
ubiquitination (Figures 2.2b-d).  
We further examined whether the ability of these RPs to regulate Mdm2 
levels had an impact on p53 levels. As shown in Figure 2.3a, when each RP was 
co-expressed in U2OS cells along with Flag-Mdm2 and HA-p53, they were able 
to inhibit Mdm2-mediated degradation of p53. More significantly, levels of 
endogenous Mdm2 and p53 in U2OS cells were elevated following expression of 
each RP in a dose-dependent manner (Figures 2.3b-d). Note as well that levels 
of p21 protein were increased along with p53. 
Consistent with the above observations, cycloheximide chase assays 
revealed that the half-life of p53 was dramatically increased by the addition of 
each RP (Figures 2.4a-c). RPL37 was able to roughly double the half-life of p53, 
while RPS15 and RPS20 were able to extend the half-life of p53 by more than 4-
fold. The underlying mechanism responsible for the ability of each RP to inhibit 
Mdm2-mediated degradation of p53 was obtained from experiments showing that 
that each RP inhibits Mdm2-mediated ubiquitination of p53 in vivo (Figures 2.4d-
f). Together, these data suggest that ectopically expressed RPL37, RPS15, and 
RPS20 regulate Mdm2 and p53 levels by binding to Mdm2 and inhibiting its E3 





   
 
RPL37, RPS15, and RPS20 increase cell death and cell cycle arrest 
To examine the physiological consequence of the ectopic expression of 
RPL37, RPS15, or RPS20, we examined the cell cycle profiles of U2OS cells 
transfected with each of the RPs by FACS analysis. We found the 
overexpression of each of the three RPs was able to modestly, but significantly, 
increase the sub-G1 content of transfected U2OS cells in a dose-dependent 
manner, indicating that they can facilitate programmed cell death in this setting 
(Figure 2.5a). Surprisingly, RPL37 expression had only a negligible impact on the 
proportion of cells in G1 phase even though p21 protein levels were increased 
(Figure 2.3b). Instead, we found that RPL37 mediated a significant G2 arrest and 
a mild drop in S phase (Figures 2.5b-d). In the case of RPS15, a significant G2 
arrest was seen with a mild drop in G1 phase, and the G2 arrest mediated by 
RPS20 correlated with modest drops in both G1 and S phases (Figures 2.5b-d). 
p21 has previously been shown to mediate G2 arrest in response to gamma 
irradiation (Bunz et al., 1998), but it remains possible that a different target (or 
targets) of p53 is regulated by the three RPs to cause cells to arrest in G2. 
 
Stabilization of p53 by RPL37, RPS15, and RPS20 leads to upregulation of 
specific p53 targets 
Upon treatment of cells with agents such as actinomycin D (ActD) or 5-





   
activate its myriad downstream target genes. Since it is possible that one of the 
modes by which such ribosomal stress activates p53 is through freed RPs arising 
from nucleolar disruption, we sought to determine how the three RPs that we 
characterized in this study affect the transcriptional activity of p53. As a 
transcription factor, p53 increases expression of genes which can participate in 
cell cycle arrest (such as p21) or apoptosis (such as Bax, Noxa, and Puma) or 
both (such as miR-34a, a micro RNA target of p53 (Hermeking, 2007) that 
indirectly causes an increase in p21 and Puma expression by inhibiting Sirt1 
(Yamakuchi et al., 2008)). p53 can also regulate metabolic flux through targets 
such as TIGAR (Bensaad et al., 2006) and can regulate itself through targets 
such as Mdm2 (Wade et al., 2013) and Ccng1 (Ohtsuka et al., 2004; Okamoto et 
al., 2002). As mentioned above, the ability of certain RPs to stabilize p53 with an 
ensuing cell outcome has been well documented. With few exceptions (Mahata 
et al., 2012; Morgado-Palacin et al., 2012), the impact of RPs on the ability of 
p53 to regulate its various target genes has not been examined. We therefore 
checked a few select but key p53 responsive genes for an in vivo response to 
ectopic expression of RPL37, RPS15, and RPS20.  
Interestingly, not only did different p53 target genes vary in their response 
to ectopic RP expression, the 3 RPs differed among themselves in their ability to 
regulate expression of some of these genes. Consistent with our observation that 
RPL37, RPS15, and RPS20 could cause a dose-dependent increase in p21 





   
when each of the 3 RPs were expressed (Figure 2.6a). Expression of each RP 
also led to increased Puma mRNA levels (Figure 2.6b). In other cases, p53 
target genes were induced by only a subset of the three RPs. Specifically, 
RPS15 and RPS20, but not RPL37, were able to increase mRNA levels of Mdm2 
(Figure 2.6c) and miR-34a (Figure 2.6d) in a dose-dependent manner. Finally, 
expression of a third category of p53 targets (Ccng1, Bax, Noxa and Tigar) was 
not affected by these RPs to a significant degree (Figure 2.S4a-d).  
 
Downregulation of MdmX protein levels by RPL37, RPS15, and RPS20 
 To further investigate possible differences in the in vivo functions of 
RPL37, RPS15, and RPS20, we asked whether they may play a role in the 
regulation of MdmX. RPL11 was previously shown to indirectly downregulate 
MdmX levels in a Mdm2-ubiquitination dependent manner (Gilkes et al., 2006), 
but the ability of other RPs to regulate MdmX has not been explored. When the 
RPs were immunoprecipitated from H1299 cell lysates transfected with individual 
Myc-tagged RPs and HA-tagged MdmX, RPS15 and RPS20 but not RPL37 co-
immunoprecipitated with MdmX (Figures 2.7a-c). It is interesting that RPS15 and 
RPS20 were the RPs that exhibited weak interactions with the N-terminal and 
RING domains of Mdm2, while RPL37 did not interact with those regions of 
Mdm2 (Figure 2.1e, Figures 2.S2). The N-terminal domains of Mdm2 and MdmX 





   
the RING domains of Mdm2 and MdmX are the sites of interaction between the 
two Mdm proteins (Linke et al., 2008; Tanimura et al., 1999). 
Despite the absence of a physical interaction between RPL37 and MdmX 
proteins, ectopic expression of RPL37 was able to cause a dose-dependent drop 
in MdmX levels (Figure 2.7d), as were RPS15 and RPS20 (Figures 2.7e-f). As a 
possible explanation for the apparent contradiction between RPL37 regulating 
MdmX protein levels without binding to the protein, levels of MdmX mRNA were 
assayed. RPL37, but not RPS15 and RPS20, was able to cause a reduction in 
MdmX mRNA levels (Figure 2.7g), suggesting it has a different mechanism for 
regulating MdmX protein levels than the other RPs. 
 
Knockdown of RPL37, RPS15, and RPS20 by siRNA increase levels of p53 
and p21 but decrease levels of MdmX 
 As mentioned in the Introduction, siRNA-mediated depletion of some RPs 
that were shown to interact with Mdm2 is correlated with a decrease in p53 
levels, while reduction of other RPs by siRNA was shown to perturb ribosomal 
biogenesis and lead to activation of p53. RPL37 was previously reported to fall in 
the latter category of RPs, as a siRNA targeting RPL37 was shown to activate 
p53 (Llanos and Serrano, 2010). Indeed, using a different siRNA sequence to 
deplete RPL37 also led to upregulation of p53 and p21 (Figure 2.8a). Similarly, 
siRNA mediated ablation of RPS15 and RPS20 led to upregulation of p53 and 





   
 The effect of siRNA-mediated knockdown of RPs on MdmX other than 
siRPL11 (Gilkes et al., 2006) has not been widely reported. Here we found that 
siRPL37, siRPS15, and siRPS20 could also lead to a decrease in MdmX protein 
levels. Given the uniformity of this response, it is possible that, just like stressing 
cells with low doses of ActD leads to MdmX degradation, depleting RPs may 





   
DISCUSSION 
The three ribosomal proteins that are the focus of this paper have each 
been previously implicated in activating p53 or suppressing cancer. Ablation of 
RPL37 by siRNA was shown to disrupt ribosomal biogenesis and upregulate p53 
(Llanos and Serrano, 2010), and also lead to the upregulation of a variety of p53 
targets (Morgado-Palacin et al., 2012). A case of Diamond-Blackfan anemia, a 
heritable human disorder characterized by a predisposition to cancer, was 
identified where RPS15 had been mutated (Gazda et al., 2008). In a genetic 
screen, RPS15 was identified as a haploinsufficient tumor suppressor in 
zebrafish (Amsterdam et al., 2004). Similarly, a mouse carrying a mutation in 
RPS20 was found to have activated p53 that leads to both anemia (due to an 
increase in apoptosis of erythrocytes) and darkened skin (due to an increase in 
the proliferation of melanocytes) (McGowan et al., 2008). Here we show that 
ablation of these three RPs by siRNA can lead to increased levels of p53, as can 
overexpression.  
The experiments in this study have relied extensively on analysis of 
ectopically expressed ribosomal proteins. As such, they have both confirmed and 
extended observations made with other RPs, which, when similarly introduced 
into cells, lead to inhibition of Mdm2 activity and thereby stabilization of both p53 
and Mdm2. While arguments that ectopically expressed proteins may be present 
at levels that are non-physiologically high are certainly valid in the case of many 





   
proteins in the cell, and the amount that we are adding to the cellular pool is 
therefore unlikely to make a significant difference. Rather what we think we are 
accomplishing in our experiments is mimicking the situation that occurs upon 
ribosomal stress, which features nucleolar disruption and dispersal of free 
ribosomal proteins. Although some ribosomal proteins are rapidly degraded after 
some forms of ribosomal stress, others (RPL5 and RPL11) are stable (Bursac et 
al., 2012). To gain more insight into the likely roles of these proteins, it might be 
appropriate to further examine the consequences of depletion of these RPs on 
the p53 pathway in future studies. However, there are arguments that such 
approaches might not be that informative. In many cases, knockdown of RPs 
induces rather than suppresses activation of p53 due to the relationship between 
RPL11 and other RPs first noted by Thomas and colleagues (Fumagalli et al., 
2009) and later by Dai and colleagues (Sun et al., 2010), and siRPL37, siRPS15, 
and siRPS20 may function similarly. The former found that disruption of 40S 
ribosome biogenesis mediated by siRPS6 causes arrest of the cell cycle in an 
RPL11-dependent manner, and the latter found that perturbation of 60S 
ribosome biogenesis mediated by siRPL29 or siRPL30 results in a similar 
outcome. A second argument is that siRNAs targeting even the same RP (e.g. 
RPS7) seem to provide different results in different reports (e.g. compare (Chen 
et al., 2007) and (Zhu et al., 2009) versus (Fumagalli et al., 2012) and (Bursac et 
al., 2012)). Therefore, we feel that the results in this paper provide new 





   
Increasing numbers of RPs have been shown to contribute to p53 stress 
response. It was recently hypothesized that those RPs can be classified as 
“detector” RPs or “effector” RPs (Daftuar et al., 2010; Llanos and Serrano, 2010). 
Effector RPs, such as RPL11, can inhibit Mdm2-mediated ubiquitination and 
degradation of p53 when overexpressed, and most of those have also been 
shown to attenuate the response to stress when knocked down by siRNA. On the 
other hand, detector RPs, such as RPL7A, RPL24, RPL29, RPL30, RPL37, 
RPS6, RPS23, and RPS9 (Barkic et al., 2009; Fumagalli et al., 2009; Lindstrom 
and Nister, 2010; Llanos and Serrano, 2010; Sun et al., 2010), have an effect on 
p53 levels only when reduced by siRNA ─ they do not co-immunoprecipitate with 
Mdm2 and have no effect on p53 levels when they are overexpressed. These 
RPs appear to contribute to the p53 stress response by triggering an increase in 
levels or activity of RPL11 (Sun et al., 2010), and are thus indirect regulators of 
p53. Prior evidence suggests RPL37, RPS15, and RPS20 are detector RPs, as 
knockdown of RPL37 by siRNA (Llanos and Serrano, 2010) or mutation of 
RPS15 (Amsterdam et al., 2004) and RPS20 leads to p53 activation or 
tumorigenicity (McGowan et al., 2008). Nevertheless, our experiments suggest 
that they can also be seen as effector-type regulators of p53. We observed that 
RPL37, RPS15, and RPS20 can bind Mdm2, inhibit degradation of Mdm2 and 
p53, cause apoptosis and cell cycle arrest in G2, upregulate p21 and Puma 
mRNAs, and downregulate MdmX protein levels. Intriguingly, stable cell lines 





   
2010). The discrepancy between our results and theirs may due to the fact that 
the experiment we carried out used transient transfection while they were using 
cell lines harboring a GFP-tagged protein. 
Currently, it is quite mysterious why so many RPs play seemingly 
redundant roles in regulating levels of p53. One conclusion to draw from the 
surfeit of RPs that can regulate the Mdm2-p53 axis is that ribosomal biogenesis 
is a hugely complex process and responding to interruptions in it is vitally 
important. It is possible that perturbation to the beginning, middle, or ending 
stages of ribosomal biogenesis generate specific stress signals that activate 
different RPs that go on to signal to the Mdm2-p53 axis. Also, different RPs may 
mediate p53 activation with different kinetics upon stress stimuli to ensure a 
proper cellular response. Finally, different RPs may target Mdm2 or p53 in 
different ways, such as inhibiting degradation of p53 protein or stimulating 
translation of p53 mRNA, as RPL26 does (Takagi et al., 2005). 
As each RP is studied in more detail, it is possible that more differences 
will appear in the downstream consequences of their ability to activate p53. For 
example, we observed RPL37, RPS15, and RPS20 could stimulate G2 arrest, 
while RPL23, RPS7 and RPS25 have been shown to stimulate G1 arrest (Dai et 
al., 2004; Zhang et al., 2013; Zhu et al., 2009). Additionally, we have shown that 
RPL37, RPS15, and RPS20 differ from each other in their impacts on various 
p53 targets. A recent study showed knockdown of RPL37 in mouse embryonic 





   
p53 targets including p21, Mdm2, Pidd, Puma, Noxa, and Bax (Morgado-Palacin 
et al., 2012), while we found the ectopic expression of RPL37 in human 
osteosarcoma cells led to the selective upregulation of p21 and Puma but not 
Mdm2, Noxa or Bax. Furthermore, we found that only RPS15 and RPS20 have 
the ability to upregulate additional p53 targets, namely Mdm2 and miR-34a 
mRNAs. It remains to be seen if these RPs can be found at the promoters of 
these upregulated p53 targets, as was recently shown for RPL11 and various 
p53 targets following ActD treatment (Mahata et al., 2012). Since ChIP 
experiments rely on antibodies that can efficiently immunoprecipitate the protein 
of interest, and such antibodies are presently lacking for these RPs, those 
experiments will need to wait for the development of the appropriate reagents. 
RPS15 and RPS20 were also the only RPs that could co-immunoprecipitate with 
MdmX and downregulate MdmX protein levels, while RPL37 could downregulate 
both MdmX mRNA and protein levels without physically interacting with the 
MdmX protein. It is possible that RPS15 and RPS20 may function like RPL11 
and regulate MdmX protein levels by enhancing Mdm2-mediated degradation 
(Gilkes et al., 2006), while RPL37 may use a mRNA-based mechanism to 
regulate MdmX levels. As these differences are explored in future studies, it is 
likely the model of segregating RPs into effectors versus detectors may need to 
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FIGURE LEGENDS 
Figure 2.1. RPL37, RPS15, and RPS20 interact with Mdm2. (a-c) Association 
of ectopically expressed RPs and Mdm2. H1299 cells were transfected with 
Flag-Mdm2 (1.2 µg), Myc-RP (1.2 µg), or both. (0.1 µg GFP was added as a 
control for transfection efficiency.) Cells were then lysed and subjected to 
immunoprecipitation and immunoblotting (IP) with the indicated antibodies as 
described. (d) Association of endogenously expressed RPs and Mdm2. 
SJSA cell lysates were subjected to immunoprecipitation with α-Mdm2, and co-
immunoprecipitation of each RP was detected by immunoblotting with the 
relevant antibody. Since RPL37 and RPS20 run very close together, 2 
independent blots are shown. In the left panel, RPL37 was blotted first and 
RPS15 second; in the right panel, RPS15 was blotted first and RPS20 was 
blotted second. Immunoblots in the right panel are taken from the same gel. (e) 
Mapping sites of interaction between RPs and Mdm2. H1299 cells were 
transfected with each Myc-RP (1.2 µg)  and various amounts of each Flag-Mdm2 
construct (full length; truncation 1-154; truncation 1-220; deletion 222-272; 
deletion 222-340; deletion 340-437; truncation 436-482) as shown in Figure 2.S2.  
Myc-RPs were immunoprecipitated with α-Myc, and co-immunoprecipitation of 
each RP and each Mdm2 construct was assayed by immunoblotting with α-Myc 
and α-Flag. Shown here is the summary of these binding assays (individual 
immunoblots are shown in Figure 2.S2). Mdm2 protein landmarks are depicted 





   
 
Figure 2.2. RPL37, RPS15, and RPS20 stabilize Mdm2. (a) Stabilization of 
ectopically expressed Mdm2 by RPs. H1299 cells were transfected with Flag-
Mdm2 (1.2 µg) and Myc-RP (1.0-3.0 µg). (GFP was added as a control for 
transfection efficiency.) Mdm2 and RP levels were detected by immunoblotting 
with α-Myc and α-Flag. (b-d) Inhibition of Mdm2 auto-ubiquitination by RPs. 
H1299 cells were seeded in 60 mM tissue culture plates and transfected with HA-
Ubiquitin (3.0 µg), Flag-Mdm2 (3.0 µg), and Myc-RP (8.0 µg for RPL37; 9.0 µg 
for RPS15 and RPS20). MG132 was added for 6 hours, and ubiquitinated Mdm2 
species were assayed by immunoprecipitating with α-Flag and immunoblotting 
with α-HA. The asterisk indicates a non-specific band that runs below Flag-
Mdm2. Inputs and IPs were run on separate gels. 
 
Figure 2.3. RPL37, RPS15, and RPS20 increase levels of p53. (a) 
Stabilization of ectopically expressed p53 by RPs. U2OS cells were 
transfected with Flag-Mdm2 (1.2 µg), HA-p53 (0.3 µg), and Myc-RP (1.0-3.0 µg). 
(GFP was added as a control for transfection efficiency.) Ectopic Mdm2, p53, and 
RP levels were detected by immunoblotting with α-Flag, α-HA and α-Myc. (b-d) 
Stabilization of endogenously expressed p53 by RPs. U2OS cells were 
transfected with increasing amounts of Myc-RP (0-3.0 µg), and endogenous 






   
Figure 2.4. RPL37, RPS15, and RPS20 stabilize p53 protein. (a-c) Increase in 
half-life of p53 by RPs. U2OS cells were seeded in 35mM tissue culture plates 
and transfected with empty vector (3.0 µg) or Myc-RP (3.0 µg). Approximately 22 
hours after the initial transfection, 100 µg/mL cycloheximide was added to the 
culture medium and cells were harvested at the indicated timepoints. (d-f) 
Inhibition of Mdm2-mediated ubiquitination of p53 by RPs. H1299 cells were 
seeded in 60mM tissue culture plates and transfected with HA-Ubiquitin (3.0 µg), 
p53 (0.75 µg), Flag-Mdm2 (7.5 µg), and Myc-RP (9.0 µg). MG132 was added for 
6 hours, and ubiquitinated p53 species were assayed by immunoprecipitating 
with α-p53 and immunoblotting with α-HA. Inputs and IPs were run on separate 
gels. 
 
Figure 2.5. Ectopic expression of RPL37, RPS15, and RPS20 increases cell 
death and G2 arrest. (a-d) Increase in Sub-G1 and G2 by RPs. U2OS cells 
were seeded in 60mM tissue culture plates and transfected with increasing 
amounts of Myc-RP (0-7.5 µg). Cell cycle analysis was carried out as described 
and normalized to the 0 µg Myc-RP control. The average of at least 3 
independent experiments is plotted, and asterisks indicate where significant 
changes were observed in the cell cycle profile (* = p<0.05; ** = p<0.01; n > 3).  
 
Figure 2.6. Ectopic expression of RPL37, RPS15, and RPS20 induces 





   
U2OS cells were seeded in 60mM tissue culture plates and transfected with 
increasing amounts of Myc-RP (0-7.5 µg). Relative expression of each gene was 
determined in triplicate by quantitative RT-PCR and normalized to GAPDH. A 
representative experiment is plotted, and significant changes in mRNA levels 
were calculated using student’s t-test (* = p<0.05; ** = p<0.01; n > 3). 
 
Figure 2.7. RPL37, RPS15, and RPS20 bind to and regulate MdmX levels. (a-
c) Association of RPs and MdmX. H1299 cells were transfected with HA-
MdmX (0.5 µg), Myc-RP (1.2 µg), or both. (GFP was added as a control for 
transfection efficiency.) Ectopic MdmX and RP levels were detected by 
immunoblotting with α-MdmX and α-Myc.  Inputs and IPs were run on separate 
gels. (d-f) Decrease in MdmX protein by RPs. U2OS cells were transfected 
with increasing amounts of Myc-RP (0-2.0 µg). Endogenous proteins were 
detected by immunoblotting with the indicated antibodies. (g) Decrease in 
MdmX mRNA by RPL37. U2OS cells were seeded in 60mM tissue culture plates 
and transfected with Myc-RP (0-5.0 µg). Relative expression of MdmX mRNA 
was determined by quantitative RT-PCR and normalized to GAPDH. A 
representative experiment is plotted, and significant changes in mRNA levels 
were calculated using student’s t-test (* = p<0.05; ** = p<0.01; n > 3). 
 
Figure 2.8. Knockdown of RPL37, RPS15, and RPS20 activate p53. (a-c) 





   
targeting RPL37, RPS15, or RPS20 as indicated (0 nM, 50 nM, 100 nM, 200 
nM). Cells were harvested and lysates were subjected to immunoblotting for 
Mdm2, MdmX, p53, p21, and the indicated RPs with the relevant antibodies. 





   
SUPPORTING INFORMATION MATERIALS AND METHODS 
Immunofluorescent microscopy 
H1299 cells were transfected with Flag-Mdm2 and Myc-RPs as indicated. 24 
hours after transfection, cells were fixed and immunostaining were carried out as 
previously described in [Karni-Schmidt O, Friedler A, Zupnick A, McKinney K, 
Mattia M, et al. (2007) Energy-dependent nucleolar localization of p53 in vitro 
requires two discrete regions within the p53 carboxyl terminus. Oncogene 26: 
3878-3891]. Rabbit polyclonal anti-Myc (Sigma) and mouse monoclonal anti-Flag 
(Sigma) antibodies were used to detect Myc-RPs and Flag-Mdm2, respectively. 
Anti-rabbit Alexa Fluor 594 (Molecular Probes) and anti-mouse Alexa Fluor 488 
(Molecular Probes) were used as secondary antibodies. Images were analyzed 
by confocal laser scanning microscopy (Model 1x81, Olympus) using Fluoview 





   
SUPPORTING INFORMATION LEGENDS 
Figure 2.S1. RPL37, RPS15, and RPS20 interact with Mdm2 in U2OS cells. 
(a-c) U2OS cells were transfected with Flag-Mdm2 (1.2 µg), Myc-RP (1.2 µg), or 
both. (GFP was added as a control for transfection efficiency.) Cells were then 
lysed and subjected to immunoprecipitation and immunoblotting (IP) with the 
indicated antibodies as described. 
 
Figure 2.S2. RPL37, RPS15, and RPS20 interact with the central region of 
Mdm2. (a) H1299 cells were transfected with Myc-RPL37 (1.2 µg), Flag-Mdm2 
full length (1.2 µg), Flag-Mdm2 truncation 1-220 (0.1 µg), Flag-Mdm2 deletion 
222-272 (1.2 µg), Flag-Mdm2 deletion 222-340 (1.1 µg), Flag-Mdm2 deletion 
340-437 (0.1 µg), and Flag-Mdm2 truncation 436-482 (0.5 µg). (b) H1299 cells 
were transfected with Myc-RPS15 (1.2 µg), Flag-Mdm2 full length (1.2 µg), Flag-
Mdm2 truncation 1-154 (1.2 µg), Flag-Mdm2 truncation 1-220 (0.1 µg), Flag-
Mdm2 deletion 222-272 (1.2 µg), Flag-Mdm2 deletion 222-340 (0.5 µg), Flag-
Mdm2 deletion 340-437 (0.25 µg), and Flag-Mdm2 truncation 436-482 (0.25 µg). 
(c) H1299 cells were transfected with Myc-RPS20 (1.2 µg), Flag-Mdm2 full length 
(1.2 µg), Flag-Mdm2 truncation 1-154 (0.04 µg), Flag-Mdm2 truncation 1-220 
(0.02 µg), Flag-Mdm2 deletion 222-272 (1.95 µg), Flag-Mdm2 deletion 222-340 
(1.0 µg), Flag-Mdm2 deletion 340-437 (0.1 µg), and Flag-Mdm2 truncation 436-
482 (0.3 µg). (d) H1299 cells were transfected with Myc-RPS20 (1.2 µg) and 





   
220, deletion 222-340, deletion 340-437, truncation 438-483). (e) H1299 cells 
were transfected with Myc-RPS20 (1.2 µg), Flag-Mdm2 full length (1.2 µg), Flag-
Mdm2 truncation 1-220 (0.3 µg), Flag-Mdm2 deletion 222-340 (0.9 µg), Flag-
Mdm2 deletion 340-437 (0.3 µg), and Flag-Mdm2 truncation 436-482 (0.4 µg). 
For all transfections, Myc-RPs were immunoprecipitated with α-Myc and co-
immunoprecipitation of each RP and each Mdm2 construct was assayed by 
immunoblotting with α-Myc and α-Flag. In panels (b)-(d), inputs and IPs were run 
on separate gels. 
 
Figure 2.S3. RPL37, RPS15, and RPS20 stabilization of Mdm2 seen by 
immunofluorescent microscopy. H1299 cells were grown on coverslips in 
35mM tissue culture plates and transfected with Flag-Mdm2 (1.2 µg), Myc-RP 
(1.2 µg), or both. Immunofluorescent staining was carried out as described. 
 
Figure 2.S4. RPL37, RPS15, and RPS20 do not upregulate mRNA levels of 
Ccng1, Bax, Noxa, or Tigar. U2OS cells were seeded in 60mM tissue culture 
plates and transfected with increasing amounts of Myc-RP (0-7.5 µg). Relative 
expression of each gene was determined in triplicate by quantitative RT-PCR 
and normalized to GAPDH. A representative experiment is plotted, and 
significant changes in mRNA levels were calculated using student’s t-test (* = 






   
Table 2.T1. siRNA sequences. The sequences for the siRNAs used are 
provided. 
 
Table 2.T2. qRT-PCR sequences. The primer sequences for the qRT-PCR 
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p53 is an important tumor suppressor in cells that causes cell cycle arrest 
or apoptosis in response to many forms of stress. Its activity is kept in check by 
Mdm2, an E3 ubiquitin ligase that targets p53 for degradation. Research over the 
past decade has uncovered a ribosomal protein (RP)-Mdm2-p53 pathway that is 
critical for responding to ribosomal stress. All of the RPs that have been identified 
to date that participate in the pathway bind to Mdm2, inhibit its E3 ligase function, 
activate p53, and are necessary for a full p53 response to ribosomal stress. 
Here, we present evidence that a novel extra-ribosomal function exists for 
RPL36A. RPL36A interacts with Mdm2, but leads to lower levels of p53 when 
overexpressed rather than higher. Overexpression of RPL36A also attenuates 
the response to ribosomal stress, while knockdown accentuates it. Endogenous 
RPL36A also appears to move from a soluble state to an insoluble state in 
response to ribosomal stress, suggesting that unlike other ribosomal proteins, its 






p53 is an important tumor suppressor whose loss or mutation has been 
implicated in over half over the cases of human cancer (Levine and Oren, 2009). 
It is a stress-responsive sequence-specific transcription factor with a wide variety 
of targets that can mediate many cellular outcomes (Gomez-Lazaro et al., 2004). 
In the absence of stress, p53 levels and activity are kept in check by its negative 
regulator Mdm2. Mdm2 is a RING-type E3 ubiquitin ligase that ubiquitinates and 
targets p53 for nuclear export and proteasome-mediated degradation (Haupt et 
al., 1997; Honda et al., 1997; Kubbutat et al., 1997). Mdm2 can also directly bind 
to and inhibit p53’s transactivation domain and prevent target gene activation. In 
response to stress, p53 can upregulate targets such as p21 and Puma to cause 
cell cycle arrest or apoptosis. p53 has many additional targets, one of which is 
Mdm2. The transcription of Mdm2 by p53 creates a negative feedback loop that 
shuts off p53 activity once the stress has passed. 
Many forms of stress have been shown to break the Mdm2-p53 interaction 
and upregulate p53 levels and activity. One such stress is ribosomal stress, also 
known as nucleolar stress. Ribosomal biogenesis is a complex process that 
takes place in the nucleolus, and disruptions to any of its steps can trigger stress 
that signals to p53 (Boisevert et al., 2007). Over the past decade, multiple groups 
have shown the existence of a ribosomal protein (RP)-Mdm2-p53 pathway that is 
important for the response to ribosomal stress (Deisenroth and Zhang, 2010). 




small subunit and 46 RPL’s in the 60S large subunit), and 12 of them have been 
shown to interact with Mdm2, inhibit its E3 ubiquitin ligase activity, stabilize p53 
levels and increase p53 activity. In order of discovery, they are RPL11 (Lohrum 
et al., 2003; Zhang et al., 2003), RPL23 (Dai et al., 2004; Jin et al., 2004), RPL5 
(Dai and Lu, 2004), RPS7 (Chen et al., 2007; Zhu et al., 2009), RPL26 (Zhang et 
al., 2010), RPS27 and RPS27L (Xiong et al., 2011), RPS27A (Sun et al., 2011), 
RPS14 (Zhou et al., 2013), RPS25 (Zhang et al., 2013), RPS26 (Cui et al., 
2013), RPL37, RPS15, and RPS20 (Daftuar et al., 2013). One of those 12, 
RPL26, has an additional mechanism for stimulating p53 activity; it can also 
increase p53 levels by augmenting translation of its mRNA (Takagi et al., 2005; 
Chen and Kastan, 2010). 
 Thus, the accumulated evidence suggests RPs have extra-ribosomal 
functions as tumor suppressors in the Mdm2-p53 axis. However, oncogenic 
extra-ribosomal roles for a few RPs have been identified. Overexpression of 
RPS3A in 3T3 cells led to transformation and tumor development in nude mice 
(Naora et al., 1998), although the mechanism remains unclear. And although 
RPL23 can increase p53 as described above, it can also indirectly promote Myc 
activation and cellular proliferation (Wanzel et al., 2008), suggesting its role in 
vivo may be more complex than other RPs that have only been shown to activate 
p53. However, no RPs have previously been shown to function as oncogenes 




A yeast two-hybrid screen using Mdm2 as the bait identified RPL36A and 
its closely related homolog RPL36AL as potential Mdm2 interactors. RPL36A is 
found on the X chromosome in humans, and like the other sex-linked ribosomal 
proteins (RPL39 and RPL10), an autosomal version of RPL36A exists called 
RPL36AL. The autosomal versions were likely retrotransposed from the X-linked 
genes and may have evolved to compensate for the reduced dosage of X-linked 
RP genes (Uechi et al., 2002). While the sequences of RPL36A and RPL36AL 
differ somewhat at the DNA level, they only differ at the protein level by 1 amino 
acid at position 38 (K in RPL36A; R in RPL36AL), and they can substitute for 
each other in the ribosome (Baouz et al., 2009). RPL36A is a highly basic 60S 
large subunit RP that is conserved among eukaryotic 80S ribosomes but absent 
in prokaryotic 70S ribosomes. Early studies suggested RPL36A is localized to 
the peptidyl-tRNA binding site of translating ribosomes, alongside 5 other RPs 
(Fabijanski and Pellegrini, 1981). Later studies concurred that RPL36A is found 
deep within the ribosome, buried beneath other RPs and obscured from the 
surface by 28S rRNA (Marion and Marion, 1987). 
 A few subtle hints existed previously for extra-ribosomal functions for 
RPL36A. One study found its mRNA, along with 22 other RPs, was 
downregulated during neuronal differentiation (Bevort and Leffers, 2000). 
Another study showed decreased levels of RPL36A protein in 2-week old male 
rats whose mothers had experienced chronic exposure to nitric oxide (Wesseling 




keratinocytes treated with arsenite and interacts with both RPL36A and RPS6 
outside the nucleus (Kappeler et al., 2012). Related to cancer, one study found 
RPL36A levels are upregulated in hepatocellular carcinoma (Kim et al., 2004), 
and another found that it relocalizes to the surface of cells during doxorubicin-
induced apoptosis (Nishida et al., 2002). RPL36A+/- zebrafish have impaired 
growth and a predisposition for forming nerve sheath tumors (Amsterdam et al., 
2004). We present evidence here that RPL36A has a novel extra-ribosomal role 





MATERIALS AND METHODS 
Plasmids and siRNA 
Flag-Mdm2 and its deletion constructs, GFP, HA-p53, HA-ubiquitin, p53, 
pcDNA3-Myc were described previously (Zhu et al., 2009). RPL36A was cloned 
into the pcDNA3-Myc mammalian expression vector using the following forward 
and reverse primers: 5’-GCGGATCCAGTTAACGTCCCTAAAAC-3’ and 5’-
GCGAATTCTTAGAACTGGATCACTTG-3’. RPL36AL was sub-cloned from 
RPL36A using the following forward and reverse primers: 5’-
CTGTACGCCCAGGGAAGGCGGCGTTATGACAGG-3’ and 5’-
CCTGTCATAACGCCGCCTTCCCTGGGCGTACAG-3’ (QuikChange Site-
Directed Mutagenesis Kit, Agilent). Note the sub-cloned RPL36AL has the amino 
acid sequence of RPL36AL but not its exact DNA sequence. siRPL36A and 
siRPL36AL sequences were pre-designed by the manufacturer (Hs_RPL36A_9 
SI04164454, Hs_RPL36A_10 SI04302088, Hs_RPL36AL_1 SI00706419, 
Hs_RPL36AL_2 SI00706426, Hs_RPL36AL_7 SI04250078, Qiagen), while siLuc 
(siRNA against luciferase) was previously described (Peart et al., 2010). 
 
Cell culture, transfection, and drugs 
H1299 lung carcinoma, SJSA osteosarcoma, and U2OS osteosarcoma cell lines 
were cultured as described previously (Zhu et al., 2009). Transfections were 
carried out as described previously (Daftuar et al., 2013). Briefly, DNA 




the manufacturer’s instructions (Invitrogen), and siRNA transfections were 
carried out for 72 hours with DharmaFECT 1 according to the manufacturer’s 
instructions (Thermo Scientific). The following drugs were added prior to 
harvesting for the indicated amounts of time: actinomycin D (Sigma), 
cycloheximide (Sigma), 5-fluorouracil (Sigma), or MG132 (Calbiochem). 
 
Gel electrophoresis, Coomassie Blue staining, and immunoblotting 
Gel electrophoresis and immunoblotting were carried out as described previously 
(Daftuar et al., 2013). Briefly, cell pellets were lysed with Lysis Buffer (25 mM 
Tris-Hcl pH 7.5, 137 mM NaCl, 2.7 mM KCl, and 0.5% Igepal CA-630 
supplemented with 50 nM PMSF and inhibitor cocktail containing 100uM 
Benzamidine, 300ug/uL Leupeptin, 100mg/mL Bacitracin, and 1mg/mL a2-
macroglobulin) and unless indicated otherwise, cell lysates were cleared by 
spinning at 4,000 rpm for 10 minutes. Equivalent amounts of protein were loaded 
onto polyacrylamide gels, and gels were either stained with Coomassie Brilliant 
Blue G-250 solution (Fisher) or transferred onto nitrocellulose membranes (Bio-
Rad). For immunoblots, membranes were probed using the following antibodies: 
anti-actin (A2066, Sigma); anti-Flag (M2, Sigma); anti-GFP (B2, Santa Cruz 
Biotechnology); anti-HA (16B12, Covance); anti-Mdm2 (a mixture of 3G5, 4B11, 
and 5B10 hybridomas); anti-Myc (9E10, Santa Cruz Biotechnology or C3956, 
Sigma); anti-p21 (C19, Santa Cruz Biotechnology); anti-p53 (a mixture of 1801 




Membranes were visualized either using chemiluminescence (ECL, GE 
Healthcare) or fluorescence (IRDye, LI-COR Biosciences). 
 
Immunoprecipitations 
H1299 or U2OS cells were transfected with Myc-RPL36A, Flag-Mdm2, and 
various Flag-Mdm2 truncation and deletion constructs as indicated. Anti-Myc 
(9E10, Santa Cruz Biotechnology) was used to immunoprecipitate equal 
amounts of each clarified cell lysate. Immunoprecipitations of endogenous 
proteins from confluent SJSA cells were performed using the following 
antibodies: mouse IgG (B2, Santa Cruz Biotechnology), anti-Mdm2 (SMP14, 
Santa Cruz Biotechnology), and anti-RPL36A (43A, Santa Cruz Biotechnology). 
After an overnight incubation with the antibodies, pre-blocked Protein G 
Sepharose beads (GE Healthcare) were added to the cell lysates for 1 hour. 
Unbound proteins were removed by washing four times with an excess of Lysis 
Buffer. 
 
Ubiquitination and cycloheximide assays 
Ubiquitination assays were carried out as described previously (Daftuar et al., 
2013). In the case of cycloheximide assays, 100 µg/mL cycloheximide was 
added to transfected cells for the indicated amounts of time. After 
immunoblotting, band intensities were quantified using Odyssey software (LI-




half-life of p53 protein was calculated using a one-phase exponential decay 
model (GraphPad Prism). 
 
Quantitative RT-PCR 
Quantitative RT-PCR was carried out as described previously (Daftuar et al., 
2013). Primer sequences (Table 3.S2) were validated for efficiency and 
specificity prior to the start of experimentation. 
 
Immunofluorescent microscopy 
Immunofluorescent microscopy was carried out as described previously (Daftuar 






RPL36A interacts with Mdm2 
RPL36A and its closely related homolog RPL36AL were identified as 
potential Mdm2 binding partners in a yeast two-hybrid screen (Zhu et al., 2009). 
Our first step was to validate this finding in mammalian cells. RPL36A was 
cloned into a mammalian expression vector, and RPL36AL was sub-cloned using 
site-directed mutagenesis. When Mdm2 and RPL36A were transfected into the 
H1299 lung carcinoma cell line, immunoprecipitating RPL36A allowed for the co-
immunoprecipitation of Mdm2 (Figure 3.1a). Importantly, H1299 cells are null for 
p53, indicating RPL36A can interact with Mdm2 independently of p53. On the 
other hand, the presence of p53 does not interfere with this interaction since a 
similar result was seen in U2OS cells, an osteosarcoma cell line that contains 
wildtype p53 (Figure 3.S1).  
To further validate this finding, we observed that the endogenous Mdm2 
and RPL36A proteins could co-immunoprecipitate in the SJSA osteosarcoma cell 
line (Figure 3.1b). Specifically, while the Mdm2 antibody used 
immunoprecipitated Mdm2 and co-immunoprecipitated RPL36A, the RPL36A 
antibody used did not co-immunoprecipitate Mdm2. This suggests the epitope of 
the RPL36A antibody may obscure the site of interaction with Mdm2, or that only 
a small fraction of cellular RPL36A interacts with Mdm2. It should also be noted 
that since RPL36A and RPL36AL differ by only a single amino acid, the antibody 




RPL36AL, or (most likely) both proteins. The interaction between the 
endogenous proteins also persisted in the presence of RNase, indicating their 
interaction is independent of RNA (data not shown). 
To extend the finding that RPL36A and Mdm2 can interact, we mapped 
the sites of interaction using a panel of Mdm2 deletion mutants that were 
previously generated (Zhu et al., 2009). Given the highly basic nature of 
RPL36A, we anticipated the two proteins would most likely interact via the acidic 
domain of Mdm2, which lies between residues 237 and 288. Indeed, a Mdm2 
deletion construct missing residues 222-272 failed to interact with RPL36A, as 
did a second deletion construct missing residues 222-340 (Figure 3.S2). Many of 
the ribosomal proteins that have been shown to interact with Mdm2 bind to its 
acidic domain; the remainder bind to the adjacent Zinc finger region between 
residues 288 and 331. RPS15 and RPS20 also have secondary binding sites at 
the N-terminus and C-terminus of Mdm2 (Daftuar et al., 2013) (Figure 3.1c). 
 
RPL36A downregulates p53 
We next sought to determine if the physical interaction between RPL36A 
and Mdm2 has a functional consequence in cells. Mdm2 is most famous as the 
key negative regulator of p53, so we hypothesized RPL36A would inhibit Mdm2 
and increase levels of p53. Using a standard cell-based p53 degradation assay, 
the introduction of Flag-Mdm2 to U2OS cells that were transfected with HA-p53 




added to the system, levels of p53 dropped even further (Figure 3.2a). This is in 
contrast to over a dozen other ribosomal proteins that have all been shown to 
abrogate the Mdm2-mediated degradation of p53 and upregulate p53 levels 
(Lohrum et al., 2003; Zhang et al., 2003; Dai et al., 2004; Jin et al., 2004; Dai and 
Lu, 2004; Chen et al., 2007; Zhu et al., 2009; Zhang et al., 2010; Xiong et al., 
2011; Sun et al., 2011; Zhou et al., 2013; Zhang et al., 2013; Cui et al., 2013; 
Daftuar et al., 2013). Indeed, as was previously published, we confirmed that the 
addition of RPL11 upregulated p53 levels in our assay. 
Furthermore, RPL36A was also able to downregulate levels of 
endogenous p53 in U2OS cells (Figure 3.2b). This novel phenotype is the 
opposite of what been seen for all the other RPs that have been shown to 
regulate the Mdm2-p53 axis; when any of them are overexpressed, they increase 
levels of ectopic and endogenous p53. It is possible that unlike other ectopic 
RPs, overexpression of RPL36A disrupted global protein synthesis. However, 
this is unlikely because levels of Myc-RPL36A were not very strongly 
overexpressed relative to endogenous RPL36A / RPL36AL, yet it was still able to 
exert this effect. Additionally, immunofluorescence (IF) assays showed Myc-
RPL36A localizing primarily to the nucleolus, not to the cytoplasm of H1299 cells 
(Figure 3.S3), suggesting that Myc-RPL36A, like other ectopic RPs, is being 
incorporated into newly formed 60S ribosomes and pre-existing 80S ribosomes 
within the cytoplasm are not perturbed. (The relative absence of signal in the 




RPL36A into active 80S ribosomes causes it to become inaccessible to detection 
by antibody.) 
In contrast to what was observed with ectopic Myc-RPL36A, levels of p53 
increased  when either endogenous RPL36A or RPL36AL, or both, were knocked 
down by siRNA (Figure 3.2c-e). In general, as reviewed in the Introduction 
(Chapter 1), siRNA directed against other RPs that interact with Mdm2 lead to 
decreased levels of p53 (the exceptions are siRPL23, siRPL37, siRPS14, 
siRPS15, siRPS20, and siRPS26, which also upregulate p53 levels). However, 
siRNA-mediated knockdown of many RPs that do not bind to Mdm2 also lead to 
an increase in p53 levels. In each of these latter cases, the leading hypothesis is 
that the removal of an essential RP disrupts ribosomal biogenesis and induces 
cellular stress that indirectly signals to p53. But ribosomal biogenesis may remain 
undisrupted when RPL36A is knocked down by sequence-specific siRNA that 
leaves RPL36AL levels intact (Figure 3.S4), and vice versa, since they can 
substitute for each other within the ribosome (Uechi et al., 2002; Baouz et al., 
2009). Hence, the increase in p53 levels observed upon treatment of cells with 
siRPL36A or siRPL36AL may be due to a direct signal to the Mdm2-p53 axis. 
One additional clue that siRPL36A may not disrupt ribosomal biogenesis came 
from looking at overall levels of proteins within the cell. Coomassie Blue staining 
showed that siRNA against either RPL36A or RPL36AL did not change global 
protein levels (Figure 3.S5), although we cannot rule out an effect on scarce 





RPL36A augments turnover of p53 protein 
 Our next step was to determine the mechanism by which RPL36A 
regulates p53 levels. Other ribosomal proteins that interact with Mdm2 have been 
shown to inhibit Mdm2-mediated degradation of p53 and prolong the half-life of 
the p53 protein. But unlike other ribosomal proteins, RPL36A enhanced Mdm2-
mediated ubiquitination of p53 in a dose-dependent manner (Figure 3.3a). In 
addition, the proteasome was necessary for knockdown of RPL36A or RPL36AL 
to affect p53 levels; when its function was inhibited by the addition of MG132, 
siRPL36A or siRPL36AL were no longer able to increase levels of p53 (Figure 
3.3b). In support of this finding, cycloheximide chase assays showed that 
knockdown of either RPL36A or RPL36AL increased the half-life of p53 by 
approximately two-fold. Furthermore, knockdown of both of them simultaneously 
led to an increase in the half-life of p53 in excess of 10-fold, indicating p53 
degradation was nearly completely blocked (Figure 3.3c). 
 
RPL36A inhibits the p53 response to ribosomal stress 
We next explored if the observed function interaction between RPL36A 
and the Mdm2-p53 axis has any relevance in vivo. Ribosomal stress can be 
induced by the addition of low doses of actinomycin D (ActD) or 5-fluorouracil 
(5FU) to cells. ActD is a potent inhibitor of RNA polymerase I (RNA Pol I), the 




transcribed by RNA polymerase III). At higher concentrations, ActD can also 
inhibit Pol II and thus shut down transcription of mRNA. 5FU is a derivative of 
uracil that can interfere with the synthesis of thymidine and can be incorporated 
into elongating RNA to cause cell cycle arrest. At higher doses, 5FU can also be 
incorporated into replicating DNA and cause apoptosis.  
Other ribosomal proteins that interact with Mdm2 have been shown to be 
necessary for a full response to ribosomal stress; when they are knocked down 
by siRNA, the p53 response is attenuated. On the other hand, when siRNA was 
directed against RPL36A or RPL36AL and ActD was applied, the p53 response 
was accentuated (Figure 3.4a-b). Similar results were seen for the response to 
5FU (Figure 3.4c-d). Only when RPL36A was overexpressed did the response to 
ribosomal stress become attenuated (Figure 3.4e-f). Again, this is in contrast to 
other ribosomal proteins whose siRNA-mediated ablation leads to attenuation of 
the stress response. 
 
RPL36A and RPL36AL relocalize in response to ribosomal stress 
While exploring the mechanism of how RPL36A is able to regulate the 
Mdm2-p53 axis, we observed that the ectopic Myc-RPL36A protein was quite 
unstable. It was degraded by the proteasome, and its half-life was quite short 
(Figure 3.5a-b). However, the endogenous RPL36A / RPL36AL protein was 
extremely stable, with no detectable degradation following 6 hours of 




ribosomal protein, whose half-lives are generally measured in many hours or 
days. Therefore, we were quite surprised to observe an apparent change in the 
levels of endogenous RPL36A / RPL36AL proteins in response to ribosomal 
stress (Figure 3.5d). This is in contrast to ribosomal proteins such as RPL11, 
RPL23, and RPL26, whose levels do not change in response to ribosomal stress 
(Dai et al., 2004; Zhang et al., 2010).  
One recent report found that RPS27A was degraded in response to ActD-
induced ribosomal stress (Sun et al., 2011), however we found inhibition of 
proteasomal degradation did not affect the apparent drop in RPL36A / RPL36AL 
levels (Figure 3.S6). Additionally, the levels of RPL36A and RPL36AL mRNA did 
not change in response to ribosomal stress (Figure 3.S7). However, a previous 
publication on RPL36A reported that it relocalizes to cell surfaces during 
doxorubicin-induced stress (Nishida et al., 2002), so we explored if a similar 
phenomenon could be observed during ribosomal stress. We assayed for the 
levels of RPL36A and RPL36AL levels in both a soluble-only fraction and in 
complete cell lysate. For the soluble fraction, we followed our standard practice 
of performing a brief, low-speed spin after lysis to separate out the insoluble 
membranes and debris prior to gel electrophoresis and immunoblotting. For the 
complete cell lysate, we omitted this spin and loaded the entire cell lysate onto 
the gel. As shown in Figure 3.5e, levels of RPL36A and RPL36AL were steady 
when looking at the complete cell lysate but appeared to drop in the soluble 




the gel, levels of RPL36A and RPL36AL appeared to go up in response to 
ribosomal stress (Figure 3.5f). We surmise that RPL36A and RPL36AL are re-






Over a dozen ribosomal proteins (RPs) have previously been identified as 
tumor suppressors that activate p53 (Lohrum et al., 2003; Zhang et al., 2003; Dai 
et al., 2004; Jin et al., 2004; Dai and Lu, 2004; Chen et al., 2007; Zhu et al., 
2009; Zhang et al., 2010; Xiong et al., 2011; Sun et al., 2011; Zhou et al., 2013; 
Zhang et al., 2013; Cui et al., 2013; Daftuar et al., 2013). One of those 12, 
RPL26, has an additional mechanism for stimulating p53 activity; it can also 
increase p53 levels by augmenting translation of its mRNA (Takagi et al., 2005; 
Chen et al., 2010), and several more RPs have been shown to indirectly activate 
p53 when their ablation by siRNA leads to a disruption to ribosomal biogenesis 
(Zhou et al., 2012). This led to a hypothesis that RPs could be classified as 
“effectors” or “detectors” (Llanos and Serrano, 2010; Daftuar et al., 2010). 
“Effector” RPs interact with Mdm2, increase levels of p53 when overexpressed 
by inhibiting Mdm2 mediated ubiquitination and degradation, generally decrease 
levels of p53 when knocked down by siRNA, but are necessary for a full 
response to actinomycin D-induced ribosomal stress. “Detector” RPs do not 
interact with Mdm2, do not affect p53 when overexpressed, increase p53 when 
knocked down by siRNA by causing an impairment to ribosomal biogenesis, and 
indirectly signal to the Mdm2-p53 axis through the “effector” RPL11. 
Here, we present evidence that RPL36A has a novel property as a 
ribosomal protein that can inhibit p53 rather than activate it. Based upon the 




considered a “repressor” of the Mdm2-p53 axis. Like “effector” RPs, RPL36A 
interacts with Mdm2, but unlike them, causes p53 levels to drop when 
overexpressed by enhancing Mdm2-mediated ubiquitination and degradation. 
Like “detector” RPs, knockdown of RPL36A increases levels of p53, but unlike 
either “detectors” or “effectors”, overexpression of RPL36A attenuates the p53 
response to ribosomal stress. Perhaps most relevant to what may happen in 
vivo, endogenous RPL36A relocalizes in response to ribosomal stress and this 
movement may allow for a full p53 response. 
RPL36A appears to function through enhancement of Mdm2-mediated 
degradation, but additional mechanisms for regulating p53 levels are possible. 
For example, RPL26 has multiple mechanisms for regulating p53 levels. Besides 
binding to the central acidic region of Mdm2 and inhibiting its E3 ubiquitin ligase 
activity, it can also bind to both the 5’ and 3’ UTR of p53 mRNA and stimulate its 
translation in response to irradiation (Takagi et al., 2005; Chen et al., 2010). 
Perhaps it should not be too surprising that not all RPs affect the Mdm2-
p53 axis the same way. In the case of Myc, a transcription factor that can lead to 
increased cellular proliferation, various RPs have been shown to affect its activity 
in different ways. For example, RPL11 and RPS14 can bind to and inhibit Myc 
from transactivation target genes (Dai et al., 2007; Dai et al., 2010; Zhou et al., 
2013), while RPL23 can indirectly promote Myc activation by inhibiting its 
antagonist Miz1 (Wanzel et al., 2008). RPL11 was also shown to inhibit Myc in 




(Challagundla et al., 2011). It remains to be seen if other RPs can also function 
as “repressors” of p53 like RPL36A. 
In cells, RPs are made in excess of the amount needed for ribosomal 
biogenesis (Warner and McIntosh, 2009), thus many RPs are continually 
degraded (Lam et al., 2007). If their degradation is inhibited, they may be able to 
translocate between the nucleolus and the nucleoplasm (Chen and Huang, 
2001). In that case, perhaps the “effector” subset of cellular RPs would 
inappropriately signal to p53, and RPL36A is needed to prevent this. Additionally, 
a few studies indicate excess RPL5 and RPL11 may be protected from 
degradation by pre-assembling with 5S rRNA in the nucleolus (Steitz et al., 1988; 
Zhang et al., 2007). While their preservation may serve important functions with 
respect to ribosome assembly, it has been a mystery why they do not signal to 
Mdm2 and lead to p53 activation in the absence of cellular stress. Our data may 
be the first clue in solving this mystery; RPL36A may serve as a barrier to 
inappropriate signaling to Mdm2 by RPL5 and RPL11 in the absence of 
ribosomal stress. Finally, p53 activity must be tightly controlled even in the 
presence of stress in order to prevent its theoretical pro-survival effects from 
taking over (Vousden and Prives, 2009), and perhaps RPL36A also plays a role 
in regulating p53 activity with respect to ribosomal or nucleolar stress. As more 
RPs are explored in future studies, the model of “effector”, “detector” and 
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Figure 3.1. RPL36A interacts with Mdm2. (a) Association of ectopically 
expressed RPL36A and Mdm2. H1299 cells were transfected with Flag-Mdm2 
(1.2 µg), Myc-RPL36A (1.2 µg), or both. (0.1 µg GFP was added as a control for 
transfection efficiency.) Cell lysates were subjected to immunoprecipitation (IP) 
and immunoblotting as described. (b) Association of endogenously expressed 
RPL36A and Mdm2. SJSA cell lysates were subjected to IP with α-Mdm2, and 
co-IP of endogenous RPL36A was detected by immunoblot. (c) Schematic of 
sites of interaction between RPs and Mdm2. In the upper portion, Mdm2 
protein landmarks are depicted; in the bottom portion, the regions of Mdm2 
bound by RPL36A and other published RPs are depicted. 
 
Figure 3.2. RPL36A decreases levels of p53 protein. (a) RPL36A enhances 
degradation of ectopic HA-p53. U2OS cells were transfected with Flag-Mdm2 
(1.2 µg), HA-p53 (0.3 µg), and Myc-RPs (1.0 µg). Ectopic Mdm2, p53, and RP 
levels were detected by immunoblotting with α-Flag, α-HA, and α-Myc. (b) 
Decrease in levels of endogenously expressed p53 by RPL36A. U2OS cells 
were transfected with increasing amounts of Myc-RPL36A (0-3.0 µg). (c-e) 
Knockdown of RPL36A or RPL36AL increases levels of p53. SJSA cells were 
transfected with siRNA targeting RPL36A or RPL36AL (0 nM, 50 nM, 100 nM, 
200 nM) or both (100nM or 50 nM + 50 nM in panel (e)). Cells were split into 




subjected to immunoblotting with the indicated antibodies and band intensities 
were quantified and normalized to actin. Note the RPL36A antibody cannot 
distinguish between RPL36A and RPL36AL, so a double knockdown of both is 
needed to see an effect on the protein. The relative expression of RPL36A or 
RPL36AL mRNA was determined in triplicate and normalized to GAPDH.  
 
Figure 3.3. RPL36A destabilizes p53 protein. (a) Enhancement of Mdm2-
mediated ubiquitination of p53 by RPL36A. H1299 were seeded in 60mM 
tissue culture plates and transfected with HA-Ubiquitin (3.0 µg), p53 (0.75 µg), 
Flag-Mdm2 (7.5 µg), and Myc-RPL36A (9.0-13.5 µg). 25 µM MG132 was added 
for 6 hours, and ubiquitinated p53 species were assayed by immunoprecipitating 
with α-p53 and immunoblotting with α-HA. Inputs and IPs were run on separate 
gels. (b) RPL36A and RPL36AL affect p53 levels by proteasomal 
degradation. U2OS cells were transfected with 100 nM siRNA targeting 
RPL36A, RPL36AL, or both as indicated. 30 µM MG132 was added for 6 hours, 
and cells were split into fractions for immunoblot and quantitative RT-PCR. 
Lysates were subjected to immunoblotting with the indicated antibodies and the 
relative expression of p21 mRNA was determined in triplicate and normalized to 
GAPDH.. (c) RPL36A and RPL36AL affect p53 protein half-life. U2OS cells 
were transfected with 100 nM siRNA, and approximately 71 hours after the initial 




were harvested at the indicated timepoints and cell lysates were subjected to 
immunoblotting with the indicated antibodies. 
 
Figure 3.4. RPL36A inhibits the p53 response to ribosomal stress. (a-b) 
siRNA against RPL36A and RPL36AL augments the response to 
actinomycin D (ActD). U2OS cells were transfected with 100 nM siRNA, and 
approximately 66 hours after the initial transfection, 5nM ActD was added to the 
culture medium for 6 hours. (c-d) siRNA against RPL36A and RPL36AL 
augments the response to 5-fluorouracil (5FU). SJSA cells were transfected 
with 100 nM siRNA, and approximately 66 hours after the initial transfection, 50 
µM 5FU was added to the culture medium for 6 hours. (e-f) Ectopic RPL36A 
inhibits the p53 response to both ActD and 5FU. U2OS cells were transfected 
with empty vector (3.0 µg) or Myc-RPL36A (3.0 µg). Approximately 18 hours after 
the initial transfection, 5nM ActD or 50 µM 5FU was added to the culture medium 
for 6 hours. Cells were harvested at the indicated timepoints and split into 
fractions for immunoblot and quantitative RT-PCR (qRT-PCR). Cell lysates were 
subjected to immunoblotting with the indicated antibodies, and the relative 
expression of p21 mRNA was determined in triplicate and normalized to GAPDH. 
 
Figure 3.5. RPL36A and RPL36AL relocalize in response to ribosomal 
stress. (a-b) Ectopic Myc-RPL36A is unstable. U2OS cells were transfected 




was added to the culture medium for 6 hours; in (b) 100 µg/mL cycloheximide 
(CHX) was added to the culture medium for the indicated amounts of time. (c) 
Endogenous RPL36A and RPL36AL are stable in the absence of stress. 100 
µg/mL CHX was added U2OS cells for the indicated amounts of time. (d-f) 
Endogenous RPL36AL and RPL36AL relocalize in the presence of 
ribosomal stress. 5 nM actinomycin D (ActD) or 50 µM 5-fluorouracil (5FU) 
were added U2OS cells (in (d) and (e)) or SJSA cells (in (f)) for the indicated 
amounts of time. In (d), the normal procedure was followed and cell lysates were 
cleared by centrifuging at 4,000 rpm for 10 minutes prior to gel electrophoresis; 
the resulting insoluble pellet was discarded. In (e), this spin was skipped and the 
complete cell lysate was loaded onto the gel. In (f), this spin was performed but 
the insoluble pellet was saved, resuspended in lysis buffer, and loaded onto the 





SUPPLEMENTAL FIGURE LEGENDS 
Figure 3.S1. RPL36A interacts with Mdm2 in U2OS cells. U2OS cells were 
transfected with Flag-Mdm2 (1.2 µg), Myc-RPL36A (1.2 µg), or both. (0.1 µg GFP 
was added as a control for transfection efficiency.) 25 µM MG132 for 6 hours 
prior to harvesting, and cell lysates were subjected to immmunoprecipitation (IP) 
and immunoblotting as described. 
 
Figure 3.S2. RPL36A interacts with the central region of Mdm2. H1299 cells 
were transfected with Myc-RPL36A (1.2 µg), Flag-Mdm2 full length (1.2 µg), 
Flag-Mdm2 truncation 1-154 (1.2 µg), Flag-Mdm2 truncation 1-220 (0.02 µg), 
Flag-Mdm2 deletion 222-272 (3.0 µg), Flag-Mdm2 deletion 222-340 (0.5 µg), 
Flag-Mdm2 deletion 340-437 (0.1 µg), and Flag-Mdm2 truncation 436-482 (0.2 
µg). Myc-RPL36A was immunoprecipitated with α-Myc, and co-IP for each Mdm2 
construct was assayed by immunoblot. Inputs and IPs were run on separate gels. 
 
Figure 3.S3. RPL36A localizes to nucleoli. H1299 cells were grown on 
coverslips in 35mM tissue culture plates and transfected with Flag-Mdm2 (1.2 
µg), Myc-RPL366A (1.2 µg), or both. Immunofluorescent staining was carried out 
as described. 
 
Figure 3.S4. siRNAs against RPL36A and RPL36AL are specific. SJSA cells 




indicated. Relative expression of each gene was determined in triplicate by 
quantitative RT-PCR (qRT-PCR) and normalized to GAPDH.  (The DNA 
sequences of RPL36A and RPL36AL differ by 32 nucleotides, so specific siRNA 
and qRT-PCR primers can be designed.) The average of 3 experiments is 
plotted, and no significant changes in RPL36A mRNA levels by siRPL36AL were 
observed using student’s t-test. The reverse was also true. 
 
Figure 3.S5. siRNAs against RPL36A and RPL36AL do not change cellular 
protein levels. U2OS cells were transfected with 100 nM siRNA targeting 
RPL36A, RPL36AL, or both as indicated. Equal amounts of cell lysates were 
separated by SDS-PAGE and stained with Coomassie Blue. 
 
Figure 3.S6. Proteasomal inhibition does not stop RPL36A or RPL36AL 
response to ribosomal stress. 5 nM actinomycin D (ActD) or 50 µM 5-
fluorouracil (5FU) were added U2OS cells for 20 hours. At that point, fresh 
solutions of ActD or 5FU combined with 25 µM MG132 were added to the cells 
for 4 hours. 
 
Figure 3.S7. RPL36A and RPL36AL mRNAs do not change in response to 
ribosomal stress. 5 nM actinomycin D (ActD) or 50 µM 5-fluorouracil (5FU) 




each gene was determined in triplicate by quantitative RT-PCR (qRT-PCR) and 
normalized to GAPDH.  (The average of 2 independent experiments is plotted.) 
 
Table 3.T1. qRT-PCR sequences. The primer sequences for the qRT-PCR 



























































Ribosomal proteins L37, S15, and S20 
In Chapter 2, we demonstrated that like several other “effector” ribosomal 
proteins (RPs), RPL37, RPS15, and RPS20 can bind to Mdm2, inhibit its E3 
ubiquitin ligase activity towards itself and p53, causing an increase in Mdm2 and 
p53 levels. As a result, select p53 targets become transcriptionally activated and 
cell cycle arrest and cell death are increased. Additionally, while the effect of 
most other “effector” RPs on MdmX is unknown, we were able to demonstrate 
RPL37, RPS15, and RPS20 can decrease its levels. Only RPL11 has been 
shown to similarly downregulate MdmX levels by enhancing Mdm2-mediated 
degradation (Gilkes et al., 2006); like RPL37, RPL11 cannot bind to MdmX 
directly. Therefore, we performed an in vivo ubiquitination assay to determine if 
RPL37, RPS15, or RPS20 can also enhance Mdm2-mediated degradation of 
MdmX. The data is preliminary, but it suggests RPL37 may be able to enhance 
Mdm2-mediated ubiquitination of MdmX (Figure 4.1a). In vivo degradation 
assays also show RPS20 can enhance Mdm2-mediated degradation of MdmX 
(Figure 4.1b). It remains unclear how RPS15 regulates MdmX protein levels, and 




The other “effector” RPs that have been shown to interact with Mdm2 also 
share an additional feature – they are necessary for a full response to ribosomal 
stress and their ablation by siRNA leads to an attenuation of the p53 response. 
On the other hand, “detector” RPs indirectly upregulate p53 levels when knocked 
down by siRNA via RPL11. Notably, even though RPS14 is an “effector” RP that 
decreases p53 levels under stressed conditions, in the absence of stress, it 
increases p53 levels in an RPL11-dependent manner (Zhou et al., 2013). 
Preliminary data suggests RPS15 may behave the same way (Figure 4.2a), and 
preliminary qRT-PCR data also suggests siRNA directed against either RPL37 or 
RPS15 may upregulate p53 targets promiscuously, while overexpression was 
selective (Figure 4.3a-b). 
Thus, RPL37, RPS15, and RPS20 may not fit into the existing model of 
“effector” and “detector” RPs. In the absence of other stress, just their ablation by 
siRNA appears to lead to a defect in ribosomal biogenesis and upregulated 
levels of p53. It remains to be seen if their ablation by siRNA attenuates to 
response to ribosomal stress or not. 
 
Ribosomal proteins L36A and L36AL 
In Chapter 3, we demonstrated a novel function for RPL36A as a 
“repressor” of the Mdm2-p53 axis. RPL36A interacts with Mdm2 and stimulates 
its E3 ubiquitin ligase activity to decrease levels of p53. Preliminary data 




amino acid sequences are 99% identical (Figure 4.4a-d). Additionally, 
unpublished data shows RPL12 may be another “repressor” RP, suggesting 
“repressors” may be a class of RPs with multiple members like “effectors” and 
“detectors” (Figure 4.4e-f). 
siRNA against RPL36A or RPL36AL leads to an upregulation in p53 
levels, which phenocopies “detector” RPs that do the same thing via RPL11. We 
hypothesized that siRPL36A or siRPL36AL differs from these other “detector” 
RPs in that ribosomal biogenesis is not disrupted so long as the other one is 
available to become part of the ribosome. But this argument would be 
strengthened if no change was observed in siRPL36A or siRPL36AL polysome 
profiles. Also, a lack of disruption to global protein synthesis by siRPL36A or 
siRPL36AL could be confirmed with a S35-methionine pulse-chase experiment. 
Additionally, unpublished data indicates RPL11 may be a confounding 
issue for the upregulation of p53 by siRPL36A or siRPL36AL. p53 levels are no 
longer elevated by siRPL36A or siRPL36AL in the absence of RPL11 (Figure 
4.5a), suggesting regulation of p53 levels may be at least partially dependent 
upon RPL11. On the other hand, although siRPL36A or siRPL36AL do not 
appear to affect levels of RPL11, a double knockdown of RPL36A and RPL36A 
appears to reduce levels of RPL11 (Figure 4.5b). This suggests the upregulation 
of p53 by siRPL36A and siRPL36AL may not be dependent upon RPL11, since a 
drop in RPL11 levels mediated by siRNA causes p53 levels to drop. It is likely 




and RPL36AL, and levels of other 40S RPs are being reduced as a 
consequence. 
Perhaps the answer may be that there are multiple pathways for RPL36A 
to downregulate p53 levels. For example, RPL26 is an “effector” that has been 
shown to upregulate p53 levels both by binding Mdm2 and inhibiting Mdm2-
mediated degradation of p53, and by binding to p53 mRNA and augmenting its 
translation (Takagi et al., 2005; Chen and Kastan, 2010; Ofir-Rosenfeld et al., 
2008; Zhang et al., 2010). The RPL11-dependent mechanism suggested by the 
siRNA experiments may function through Mdm2, while preliminary data from an 
experiment with Nutlin suggests a Mdm2-indepdendent mechanism may exist. 
Nutlin is a drug that prevents Mdm2 from interacting with p53, allowing them to 
be stabilized, but ectopic Myc-RPL36A is still able to decrease p53 levels in its 
presence (Figure 4.6a). 
Finally, the data presented in Chapter 3 suggests that RPL36A relocalizes 
from a soluble state into an insoluble state in response to ribosomal stress. While 
this may not be a unique phenotype, a preliminary fractionation experiment 
suggests that unlike other RPs, a subset of cellular RPL36A and RPL36AL exists 
outside the ribosome in the absence of stress (Figure 4.7a). The hypothesis that 
RPL36A and RPL36AL relocalizes in response to stress, and this is necessary 
for a full p53 response, would be strengthened if their localization, along with 





Why do so many ribosomal proteins interact with Mdm2? 
A growing number of RPs have been shown to impact p53 levels, either 
directly or indirectly. Both 40S RPs and 60S RPs have been implicated, and at 
first glance, there is no obvious sequence motif common to the RPs that have 
been shown to regulate p53 levels and those that haven’t. It is increasingly 
becoming important in the field to ascertain why so many RPs play seemingly 
redundant roles in the regulation of p53 levels. 
One possible explanation for the proliferation of RPs that can regulate the 
Mdm2-p53 axis is that different RPs may activate p53 with different kinetics upon 
stress. For example RPS7 seems to act early, regulating the response to ActD 
and 5FU around 6 hours following drug treatment (Zhu et al., 2009), while RPL11 
seems to be important later, around 24 hours after drug treatment (Zhang et al., 
2003). Also, different RPs may regulate in p53 in some cell types while others 
are dominant in other cell types. For example, RPL26 was shown to upregulate 
p53 in MCF7 cells (Takagi et al., 2005) while ectopic RPL11 has been shown to 
increase p53 levels in U2OS cells (Lohrum et al., 2003). It is also possible that 
multiple RPs can cooperate to activate p53 maximally in response to stress. For 
example, one paper showed that overexpression of both RPL5 and RPL11 is 
much better than either one alone at stimulating p53 (Horn and Vousden, 2008). 
It remains to be seen which “effector” RPs can synergize and which cannot. 
Finally, there may be subtle differences between the “effector” RPs in how 




ribosomal stress but not phosphorylation (Cui et al., 2013). Thus, the various 
“effector” RPs may be able to cause different p53 targets to be upregulated, and 
lead to different cellular outcomes. For example, of 8 different p53 target genes, 
ectopic RPL37 can only upregulate p21 and Puma, while RPS15 and RPS20 
were able to upregulate additional targets (Daftuar et al., 2013). Additionally, 
RPL37, RPS15, and RPS20 stimulate G2 arrest while RPL23, RPS7 and RPS25 
have been shown to stimulate G1 arrest (Dai et al., 2004; Zhu et al., 2009; Zhang 
et al., 2013). 
 It should be noted that it is possible RPL5 and RPL11 may have additional 
extra-ribosomal functions beyond the roles that other “effector” RPs have in the 
RP-Mdm2-p53 pathway. Within the realm of ribosomal biogenesis, they have 
been shown to pre-assemble with 5S rRNA before being added to the 60S large 
ribosomal subunit (Steitz et al., 1988; Zhang et al., 2007). One recent publication 
found that RPL5 and RPL11 are protected from proteasomal degradation 
following ribosomal stress (Bursac et al., 2012). Finally, a tumor-derived mutant 
of Mdm2, Mdm2-C305F fails to co-immunoprecipitate with RPL5 and RPL11, and 
a mouse model exhibits accelerated Eµ-Myc driven lymphomagenesis (Lindstrom 
et al., 2007; Macias, 2010). More research needs to be done to demonstrate if 
other effector RPs also linger following ribosomal stress, or if they can interact 






In this thesis, we identified novel extra-ribosomal functions for 4 different 
ribosomal proteins (RPs) in the Mdm2-p53 axis. The existence of an RP-Mdm2-
p53 pathway has been uncovered over the past decade, and we have added to 
the complexity of this pathway, particularly with the identification of RPL36A as a 
“repressor” of it. Data from cells suggest activation of p53 by RPs is essential for 
a proper response to ribosomal stress, and animal models and human 
“ribosomopathies” also suggest RPs may function as haploinsufficient tumor 
suppressors in vivo (Amsterdam et al., 2004; Narla and Ebert, 2010). On the 
other hand, activation of p53 by the loss of an allele of an RP appears to be 
problematic for erythrocyte proliferation, and perhaps our finding that RPL36A 




MATERIALS AND METHODS 
Other materials and methods are described in Chapters 2 and 3. 
 
Reagents 
Immunoblots for RPL11 were performed using a commercial mouse monoclonal 
antibody (3A4A7, Zymed). Nutlin-3a was prepared in DMSO and stored at room 
temperature until use (Sigma). siRNA targeting RPL11 was previously reported 
(Jin et al 2004); the target sequence is 5’-GCAUUGGUAUCUACGGCCU-3’. The 
siRPS15 sequence used in Figures 4.2 and 4.3 targets 5’-




Assays for ubiquitinated MdmX were adapted from (Xirodimas et al, 2001). 
Briefly, H1299 cells were transfected with His-Ubiquitin, HA-MdmX, Flag-Mdm2, 
and Myc-RPs as indicated. 18 hours after transfection, H1299 cells were treated 
with 25 µM MG132 (Calbiochem) for 6 hours. Equivalent amounts of clarified cell 
lysates were incubated with 6M guanidine and pre-blocked Protein G Sepharose 
beads (GE Healthcare) then washed with 8M urea. His-proteins were eluted with 







Cellular fractionation was adapted from (Bursac et al, 2012). Briefly, U2OS cells 
were washed then lysed in low salt buffer (10 mM Hepes-NaOH pH 7.5, 10 mM 
NaCl, 2 mM MgCl2, 1 mM EDTA) supplemented with 0.3% NP-40 and 0.2% 
sodium deoxycolate. Nucleoplasmic and cytoplasmic fractions were separated by 
centrifugation at 2,800 g for 5 minutes. The resulting nucleoplasmic pellet was 
washed in low salt buffer before lysing with high salt buffer (10 mM Tris-HCl pH 
7.2, 500 mM NaCl, 50 mM MgCl2, 0.1 mM CaCl2) supplemented with 50 U 
DNase I. The nucleoplasm was then centrifuged through a sucrose cushion (20% 
sucrose, 20 mM Tris-HCl pH 7.4, 10 mM MgCl2, 300 mM KCl, 0.5% NP40) at 
149,000 g for 2 hours to separate the nuclear ribosomal pellet from the nuclear 
non-ribosomal supernatant. The non-ribosomal nuclear fraction concentrated by 
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Figure 4.1. RPL37 and RPS20 may enhance Mdm2-mediated ubiquitination 
and degradation of MdmX. (a) Preliminary data suggests possible 
enhancement of Mdm2-mediated ubiquitination of MdmX by RPL37. H1299 
cells were seeded in 60mM tissue culture plates and transfected with His-
Ubiquitin (4.0 µg), HA-MdmX (0.6 µg), Flag-Mdm2 (4.0 µg), and Myc-RPs (6.0 µg 
for RPL11; 1.2 µg for RPL37). 25 µM MG132 was added for 6 hours, and 
ubiquitinated MdmX species were assayed by isolating His-ubiquitin species and 
immunoblotting with α-MdmX. Inputs and IPs were run on separate gels. (b) 
RPS20 enhances Mdm2-mediated degradation of MdmX. U2OS cells were 
transfected with Flag-Mdm2 (2.0 µg), HA-MdmX (0.01 µg), and Myc-RPS20 (1.0 
– 3.0 µg). Ectopic Mdm2, MdmX, and RPS20 were detected by immunoblotting 
with α-Flag, α-MdmX, and α-Myc. Immunoblots in panel (b) are taken from the 
same gel. 
 
Figure 4.2. Activation of p53 by siRPS15 may be dependent upon RPL11. 
(a) Preliminary data suggests possible role for RPL11 in siRPS15-mediated 
p53 upregulation. U2OS cells were transfected with siRNA targeting RPL11 (50 
nM), RPS15 (150 nM), or both. Cells were harvested and lysates were subjected 





Figure 4.3. siRNA against RPL37 or RPS15 may activate multiple p53 
targets. (a-b) Preliminary data suggests siRNA against RPL37 or RPS15 
may activate more targets than overexpression of RPs. U2OS cells were 
transfected with increasing amounts of siRNA (0 nM, 50 nM, 100 nM, 200 nM). 
Relative expression of each gene was determined in triplicate by quantitative RT-
PCR and normalized to GAPDH. 
 
Figure 4.4. RPL36AL and RPL12 may downregulate p53. (a) Preliminary 
data suggests RPL36AL may interact with acidic region of Mdm2 like 
RPL36A does. H1299 cells were transfected with Myc-RPL36AL (1.2 µg), Flag-
Mdm2 full length (1.2 µg), Flag-Mdm2 truncation 1-220 (1.2 µg), Flag-Mdm2 
deletion 222-272 (1.2 µg), Flag-Mdm2 deletion 222-340 (1.2 µg), Flag-Mdm2 
deletion 340-437 (1.2 µg), and Flag-Mdm2 truncation 436-482 (1.2 µg). Myc-
RPL36AL was immunoprecipitated with α-Myc and co-immunoprecipitation of 
each Mdm2 construct was assayed by immunoblotting with α-Flag. Inputs and 
IPs were run on separate gels. (b-c) Preliminary data suggests RPL36AL may 
downregulate p53 levels like RPL36A and downregulate p53 targets. U2OS 
cells were seeded in 60 mM tissue culture plates and transfected with increasing 
amounts of Myc-RPL36A (0 - 7.5 µg). Cells were harvested and split into 
fractions for immunoblot and quantitative RT-PCR. Lysates were subjected to 
immunoblotting with the relevant antibodies. Relative expression of each gene 




GAPDH. (d) Preliminary data suggests RPL36AL may enhance Mdm2-
mediated ubiquitination of p53 like RPL36A does. H1299 cells were seeded 
in 60 mM tissue culture plates and transfected with HA-Ubiquitin (3.0 µg), p53 
(0.75 µg), Flag-Mdm2 (7.5 µg), and Myc-RPL36AL (9.0 – 18.0 µg). MG132 was 
added for 6 hours, and ubiquitinated p53 species were assayed by 
immunoprecipitating with a-p53 and immunoblotting with α-HA. Inputs and IPs 
were run on separate gels. (e) RPL12 interacts with Mdm2. H1299 cells were 
transfected with Myc-RPL12 (1.2 µg), Flag-Mdm2 (1.2 µg), or both. (0.1 µg GFP 
was added as a control for transfection efficiency.) MG132 was added for 6 
hours, and Myc-RPL12 was immunoprecipitated with α-Myc and co-
immunoprecipitation of Flag-Mdm2 was assayed by immunoblotting with α-Flag. 
(f) RPL12 decreases levels of p53 protein. U2OS cells were transfected with 
increasing amounts of Myc-RPL12 (0 – 3.0 µg). Endogenous proteins were 
detected by immunoblotting with the relevant antibodies. 
 
Figure 4.5. Activation of p53 by siRPL36A or RPL36AL may be dependent 
upon RPL11. (a) siRNA-mediated knockdown of RPL11 suppresses 
siRPL36A-mediated p53 upregulation. SJSA cells were transfected with siRNA 
targeting RPL11 (50 nM), RPL36A (100 nM), RPL36AL (100 nM), or 
combinations thereof. (b) Double knockdown of RPL36A and RPL36AL 




with 100 nM siRNA targeting RPL36A, RPL36AL, or both. Cells were harvested 
and lysates were subjected to immunoblotting with the relevant antibodies. 
 
Figure 4.6. RPL36A may also downregulate p53 independently of Mdm2. (a) 
RPL36A decreases levels of p53 in the presence of Nutlin. U2OS cells were 
transfected with empty vector (3.0 µg) or Myc-RPL36A (3.0 µg). 2 µM Nutlin was 
added to the culture medium for 6 hours before harvesting. Endogenous proteins 
were detected by immunoblotting with the relevant antibodies. Immunoblots are 
taken from the same gel. 
 
Figure 4.7. RPL36A and RPL36AL may exist in a ribosomal-free fraction. (a) 
Preliminary data suggests RPL36A and RPL36A may exist unbound to 
ribosomes in the nucleoplasm. U2OS cells were treated with 5nM actinomycin 
D for 0 – 5 hrs then fractionated into ribosomal nucleoplasmic fractions and non-
ribosomal nucleoplasmic fraction as described. Endogenous proteins were 
detected by immunoblotting with the relevant antibodies. 
 
 
188 
 
 
 
189 
 
 
 
190 
 
 
 
191 
 
 
 
192 
 
 
 
193 
 
 
 
194 
 
